<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput xmlns:ns2="local" hits="10" offset="0" totalResults="24"><Filters total="48"><Filter label="Trial Technologies" name="trialTechnologies" total="35"><FilterOption id="762" count="17" label="Small molecule therapeutic"></FilterOption><FilterOption id="585" count="14" label="Oral formulation"></FilterOption><FilterOption id="595" count="13" label="Tablet formulation"></FilterOption><FilterOption id="751" count="10" label="Film coating"></FilterOption><FilterOption id="648" count="5" label="Intravenous formulation"></FilterOption><FilterOption id="175" count="4" label="Drug combination"></FilterOption><FilterOption id="761" count="3" label="Biological therapeutic"></FilterOption><FilterOption id="898" count="3" label="Formulation powder"></FilterOption><FilterOption id="740" count="3" label="Infusion"></FilterOption><FilterOption id="746" count="3" label="Solution"></FilterOption><FilterOption id="647" count="3" label="Subcutaneous formulation"></FilterOption><FilterOption id="617" count="2" label="Aerosol formulation inhalant"></FilterOption><FilterOption id="586" count="2" label="Capsule formulation"></FilterOption><FilterOption id="616" count="2" label="Inhalant formulation"></FilterOption><FilterOption id="753" count="2" label="Microparticle formulation"></FilterOption><FilterOption id="1647" count="2" label="Natural product"></FilterOption><FilterOption id="80" count="2" label="Peptide"></FilterOption><FilterOption id="618" count="2" label="Powder formulation inhalant"></FilterOption><FilterOption id="85" count="2" label="Protein recombinant"></FilterOption><FilterOption id="630" count="2" label="Stereochemistry"></FilterOption><FilterOption id="90" count="2" label="Steroid"></FilterOption><FilterOption id="66" count="1" label="Antibiotic"></FilterOption><FilterOption id="111" count="1" label="Cloning technology"></FilterOption><FilterOption id="641" count="1" label="Controlled release formulation"></FilterOption><FilterOption id="805" count="1" label="Daily dosing"></FilterOption><FilterOption id="590" count="1" label="Enteric coated formulation"></FilterOption><FilterOption id="750" count="1" label="Freeze drying"></FilterOption><FilterOption id="743" count="1" label="Granule"></FilterOption><FilterOption id="651" count="1" label="Intramuscular formulation"></FilterOption><FilterOption id="559" count="1" label="Oral controlled release formulation"></FilterOption><FilterOption id="593" count="1" label="Oral liquid formulation"></FilterOption><FilterOption id="594" count="1" label="Oral suspension formulation"></FilterOption><FilterOption id="660" count="1" label="Oral sustained release formulation"></FilterOption><FilterOption id="742" count="1" label="Pellet"></FilterOption><FilterOption id="1652" count="1" label="Prodrug"></FilterOption></Filter><Filter label="Indications" name="indications" total="20"><FilterOption id="837" count="4" label="Non-insulin dependent diabetes"></FilterOption><FilterOption id="31" count="2" label="Asthma"></FilterOption><FilterOption id="3366" count="2" label="Essential hypertension"></FilterOption><FilterOption id="2549" count="2" label="Postmenopausal osteoporosis"></FilterOption><FilterOption id="3114" count="1" label="Bipolar I disorder"></FilterOption><FilterOption id="49" count="1" label="Breast tumor"></FilterOption><FilterOption id="57" count="1" label="Cardiovascular disease"></FilterOption><FilterOption id="404" count="1" label="Constipation"></FilterOption><FilterOption id="119" count="1" label="Epilepsy"></FilterOption><FilterOption id="1243" count="1" label="Gastroesophageal reflux"></FilterOption><FilterOption id="2535" count="1" label="Growth hormone deficiency"></FilterOption><FilterOption id="623" count="1" label="Head and neck tumor"></FilterOption><FilterOption id="153" count="1" label="Hepatitis C virus infection"></FilterOption><FilterOption id="178" count="1" label="Hypertension"></FilterOption><FilterOption id="3673" count="1" label="Metastatic head and neck cancer"></FilterOption><FilterOption id="3665" count="1" label="Metastatic non small cell lung cancer"></FilterOption><FilterOption id="276" count="1" label="Prostate tumor"></FilterOption><FilterOption id="3907" count="1" label="Renal insufficiency"></FilterOption><FilterOption id="1585" count="1" label="Syndrome X"></FilterOption><FilterOption id="1009" count="1" label="Urinary tract infection"></FilterOption></Filter><Filter label="Endpoint Index" name="trialEndpointIndex" total="100"><FilterOption id="1359" count="4" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Change in HbA1c"></FilterOption><FilterOption id="1626" count="3" label="Non-insulin dependent diabetes - Assessment of Adverse Events"></FilterOption><FilterOption id="1452" count="3" label="Non-insulin dependent diabetes - Assessment of lipid profiles - Assessment of Total Cholesterol"></FilterOption><FilterOption id="1454" count="3" label="Non-insulin dependent diabetes - Assessment of lipid profiles - HDL-C (High-density lipoprotein cholesterol)"></FilterOption><FilterOption id="1455" count="3" label="Non-insulin dependent diabetes - Assessment of lipid profiles - LDL-C (Low-density lipoprotein cholesterol)"></FilterOption><FilterOption id="1345" count="3" label="Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose"></FilterOption><FilterOption id="5984" count="2" label="Asthma - Assessment of Exacerbations - Exacerbation requiring hospitalization"></FilterOption><FilterOption id="5985" count="2" label="Asthma - Assessment of Exacerbations - Number/rate/frequency/duration of exacerbation"></FilterOption><FilterOption id="5986" count="2" label="Asthma - Assessment of Exacerbations - Severity of exacerbation"></FilterOption><FilterOption id="5987" count="2" label="Asthma - Assessment of Exacerbations - Time to first exacerbation"></FilterOption><FilterOption id="5983" count="2" label="Asthma - Assessment of Exacerbations"></FilterOption><FilterOption id="6082" count="2" label="Asthma - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="22537" count="2" label="End stage renal disease - Glycemic Control Analysis - Assessment of glycosylated hemoglobin (HbA1c)"></FilterOption><FilterOption id="7244" count="2" label="Head and neck tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="7264" count="2" label="Head and neck tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="7311" count="2" label="Head and neck tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="7312" count="2" label="Head and neck tumor - Assessment of adverse events"></FilterOption><FilterOption id="2" count="2" label="Hypertension - Assessment of Blood Pressure (BP) - BP control rate"></FilterOption><FilterOption id="40" count="2" label="Hypertension - Assessment of Diastolic Blood Pressure (DBP) - Seated DBP"></FilterOption><FilterOption id="176" count="2" label="Hypertension - Assessment of Inflammatory &amp; Oxidative Stress Markers - High-sensitivity C-reactive protein (hsCRP)"></FilterOption><FilterOption id="25" count="2" label="Hypertension - Assessment of Systolic Blood Pressure (SBP) - Seated SBP"></FilterOption><FilterOption id="223" count="2" label="Hypertension - Assessment of lipid profiles - Assessment of Total Cholesterol"></FilterOption><FilterOption id="225" count="2" label="Hypertension - Assessment of lipid profiles - HDL-C (High-density lipoprotein cholesterol)"></FilterOption><FilterOption id="226" count="2" label="Hypertension - Assessment of lipid profiles - LDL-C (Low-density lipoprotein cholesterol)"></FilterOption><FilterOption id="23556" count="2" label="Menopause - Assessment of Biomarkers - Assessment of bone markers"></FilterOption><FilterOption id="23553" count="2" label="Menopause - Assessment of Bone - Assessment by Bone mineral density (BMD)"></FilterOption><FilterOption id="1504" count="2" label="Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of abdominal circumference"></FilterOption><FilterOption id="1503" count="2" label="Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of body weight"></FilterOption><FilterOption id="1580" count="2" label="Non-insulin dependent diabetes - Assessment of Blood Pressure (BP)"></FilterOption><FilterOption id="1429" count="2" label="Non-insulin dependent diabetes - Assessment of Inflammatory &amp; Oxidative Stress Markers - High-sensitivity C-reactive protein (hsCRP)"></FilterOption><FilterOption id="1634" count="2" label="Non-insulin dependent diabetes - Assessment of Safety and Tolerability - Assessment of serious adverse events"></FilterOption><FilterOption id="1483" count="2" label="Non-insulin dependent diabetes - Assessment of lipid profiles - Non-HDL levels"></FilterOption><FilterOption id="1453" count="2" label="Non-insulin dependent diabetes - Assessment of lipid profiles - Triglyceride levels (TG)"></FilterOption><FilterOption id="1451" count="2" label="Non-insulin dependent diabetes - Assessment of lipid profiles"></FilterOption><FilterOption id="13771" count="2" label="Osteoporosis - Assessment of Bone - Assessment by Bone mineral density (BMD)"></FilterOption><FilterOption id="5966" count="1" label="Asthma - Assessment of Asthma Symptoms/Symptoms Score"></FilterOption><FilterOption id="5939" count="1" label="Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1)"></FilterOption><FilterOption id="5918" count="1" label="Asthma - Assessment of Pulmonary Function"></FilterOption><FilterOption id="6083" count="1" label="Asthma - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="6076" count="1" label="Asthma - Assessment of Therapy Related Outcomes - Asthma control"></FilterOption><FilterOption id="6078" count="1" label="Asthma - Assessment of Therapy Related Outcomes - Efficacy"></FilterOption><FilterOption id="6127" count="1" label="Asthma - Assessment of hospitalization"></FilterOption><FilterOption id="6067" count="1" label="Asthma - Assessment of use of Rescue Medication - Corticosteroid usage"></FilterOption><FilterOption id="6068" count="1" label="Asthma - Assessment of use of Rescue Medication - Duration of medication use"></FilterOption><FilterOption id="6069" count="1" label="Asthma - Assessment of use of Rescue Medication - Frequency/rate of medication use"></FilterOption><FilterOption id="6064" count="1" label="Asthma - Assessment of use of Rescue Medication"></FilterOption><FilterOption id="37466" count="1" label="Asthma - Health Economic Assessments - Assessment of direct cost"></FilterOption><FilterOption id="37469" count="1" label="Asthma - Health Economic Assessments - Health Services Utilization"></FilterOption><FilterOption id="6111" count="1" label="Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma control questionnaire (ACQ)"></FilterOption><FilterOption id="6108" count="1" label="Asthma - Patient Reported Outcomes/Quality of Life Assessments"></FilterOption><FilterOption id="10006" count="1" label="Bipolar disorder - Anthropometric Assessments"></FilterOption><FilterOption id="9923" count="1" label="Bipolar disorder - Assessment of Bipolar Disorder Symptoms - Assessment of mania"></FilterOption><FilterOption id="9921" count="1" label="Bipolar disorder - Assessment of Bipolar Disorder Symptoms"></FilterOption><FilterOption id="9922" count="1" label="Bipolar disorder - Assessment of Co-morbidity - Assessment of depression"></FilterOption><FilterOption id="9937" count="1" label="Bipolar disorder - Assessment of Depression Severity by Specific Criteria - Assessment by Montgomery-Asberg Depression Scale (MADRS)"></FilterOption><FilterOption id="10037" count="1" label="Bipolar disorder - Assessment of Disease Relapse/Recurrence - Assessment of time to recurrence"></FilterOption><FilterOption id="9932" count="1" label="Bipolar disorder - Assessment of Manic Symptoms by Specific Scales - Assessment by Young Mania Rating Scale (YMRS)"></FilterOption><FilterOption id="10020" count="1" label="Bipolar disorder - Assessment of Metabolic Parameters"></FilterOption><FilterOption id="10045" count="1" label="Bipolar disorder - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="9954" count="1" label="Bipolar disorder - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)"></FilterOption><FilterOption id="9952" count="1" label="Bipolar disorder - Assessment of Psychiatric Symptoms"></FilterOption><FilterOption id="10027" count="1" label="Bipolar disorder - Assessment of Safety and Tolerability - Assessment of extra pyramidal symptoms"></FilterOption><FilterOption id="10025" count="1" label="Bipolar disorder - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="9926" count="1" label="Bipolar disorder - Assessment of Therapy Related Outcomes - Assessment of symptom improvement"></FilterOption><FilterOption id="10026" count="1" label="Bipolar disorder - Assessment of adverse events"></FilterOption><FilterOption id="8983" count="1" label="Breast tumor - Assessment of Biopsy/Cytology/Histology"></FilterOption><FilterOption id="9011" count="1" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of systemic toxicity"></FilterOption><FilterOption id="8998" count="1" label="Breast tumor - Assessment of adverse events"></FilterOption><FilterOption id="9315" count="1" label="Breast tumor - Imaging/Radiological Assessments - Assessment by ultrasonography"></FilterOption><FilterOption id="22532" count="1" label="End stage renal disease - Assessment of Biomarkers - Assessment of other inflammatory/oxidative stress markers"></FilterOption><FilterOption id="22506" count="1" label="End stage renal disease - Assessment of Glomerular Filtration Rate (GFR) - Assessment of Estimated Glomerular Filtration Rate(eGFR)/Creatinine Clearance(CCr/CrCl/CLcr)"></FilterOption><FilterOption id="22596" count="1" label="End stage renal disease - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="22559" count="1" label="End stage renal disease - Assessment of Nutritional Status"></FilterOption><FilterOption id="22507" count="1" label="End stage renal disease - Assessment of Serum Creatinine"></FilterOption><FilterOption id="22511" count="1" label="End stage renal disease - Assessment of Urinary Protein Excretion/Proteinuria - Assessment of proteinuria/albuminuria/macroalbuminuria"></FilterOption><FilterOption id="22543" count="1" label="End stage renal disease - Assessment of lipid profiles"></FilterOption><FilterOption id="17119" count="1" label="Epilepsy - Patient Reported Outcomes/Quality of Life Assessments - Assessment of acceptability of therapy"></FilterOption><FilterOption id="7324" count="1" label="Head and neck tumor - Assessment of Chemotherapy Induced Toxicity"></FilterOption><FilterOption id="7275" count="1" label="Head and neck tumor - Assessment of Clinical Response"></FilterOption><FilterOption id="7292" count="1" label="Head and neck tumor - Assessment of Markers of Tumor Growth and Progression"></FilterOption><FilterOption id="7256" count="1" label="Head and neck tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="7263" count="1" label="Head and neck tumor - Assessment of Response Rates (RR)"></FilterOption><FilterOption id="7327" count="1" label="Head and neck tumor - Assessment of Safety and Tolerability - Assessment of chemotherapy induced nausea and vomiting"></FilterOption><FilterOption id="7313" count="1" label="Head and neck tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="7260" count="1" label="Head and neck tumor - Assessment of Survival - Assessment of median survival"></FilterOption><FilterOption id="7290" count="1" label="Head and neck tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"></FilterOption><FilterOption id="7299" count="1" label="Head and neck tumor - Patient Reported Outcomes/Quality of Life Assessments"></FilterOption><FilterOption id="9434" count="1" label="Hepatitis C virus infection - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="3809" count="1" label="Hepatitis C virus infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="3808" count="1" label="Hepatitis C virus infection - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="78" count="1" label="Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - 24-hour mean ADBP"></FilterOption><FilterOption id="82" count="1" label="Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Day-time mean ADBP"></FilterOption><FilterOption id="86" count="1" label="Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Night-time mean ADBP"></FilterOption><FilterOption id="3" count="1" label="Hypertension - Assessment of Blood Pressure (BP) - BP response rate"></FilterOption><FilterOption id="1" count="1" label="Hypertension - Assessment of Blood Pressure (BP)"></FilterOption><FilterOption id="44" count="1" label="Hypertension - Assessment of Diastolic Blood Pressure (DBP) - Trough DBP"></FilterOption><FilterOption id="31" count="1" label="Hypertension - Assessment of Diastolic Blood Pressure (DBP)"></FilterOption><FilterOption id="245" count="1" label="Hypertension - Assessment of Glomerular Filtration Rate (GFR)"></FilterOption><FilterOption id="170" count="1" label="Hypertension - Assessment of Hemoglobin A1c (HbA1c) Levels"></FilterOption><FilterOption id="220" count="1" label="Hypertension - Assessment of Insulin Sensitivity - Matsuda index/ISI by oral glucose tolerance test (OGTT)"></FilterOption></Filter><Filter label="Trial Drug Phase Highest" name="trialDrugPhaseHighest" total="3"><FilterOption id="L" count="18" label="Launched"></FilterOption><FilterOption id="DX" count="2" label="Discontinued"></FilterOption><FilterOption id="NDR" count="1" label="No Development Reported"></FilterOption></Filter><Filter label="Trial Company Sponsor" name="trialCompaniesSponsor" total="11"><FilterOption id="14190" count="12" label="AstraZeneca plc"></FilterOption><FilterOption id="15065" count="3" label="Bristol-Myers Squibb Co"></FilterOption><FilterOption id="22586" count="1" label="Boehringer Ingelheim Corp"></FilterOption><FilterOption id="1020322" count="1" label="Daiichi Sankyo Inc"></FilterOption><FilterOption id="1016499" count="1" label="Digna Biotech SL"></FilterOption><FilterOption id="17810" count="1" label="Eli Lilly &amp; Co"></FilterOption><FilterOption id="29708" count="1" label="Ferring Pharmaceuticals SA"></FilterOption><FilterOption id="22186" count="1" label="Solvay Pharmaceuticals Inc"></FilterOption><FilterOption id="22784" count="1" label="UCB Pharma Inc"></FilterOption><FilterOption id="27724" count="1" label="Warner Chilcott plc"></FilterOption><FilterOption id="14112" count="1" label="Wyeth"></FilterOption></Filter><Filter label="Trial Recruitment Status" name="trialRecruitmentStatus" total="2"><FilterOption id="4" count="23" label="Completed"></FilterOption><FilterOption id="6" count="1" label="Terminated"></FilterOption></Filter><Filter label="Trial Commercially Significant" name="trialIsCommerciallySignificant" total="2"><FilterOption id="YES" count="16" label="Yes"></FilterOption><FilterOption id="NO" count="8" label="No"></FilterOption></Filter><Filter label="Trial Indications Pioneer" name="trialIndicationsPioneer" total="7"><FilterOption id="3366" count="1" label="Essential hypertension"></FilterOption><FilterOption id="2535" count="1" label="Growth hormone deficiency"></FilterOption><FilterOption id="153" count="1" label="Hepatitis C virus infection"></FilterOption><FilterOption id="837" count="1" label="Non-insulin dependent diabetes"></FilterOption><FilterOption id="3907" count="1" label="Renal insufficiency"></FilterOption><FilterOption id="1585" count="1" label="Syndrome X"></FilterOption><FilterOption id="1009" count="1" label="Urinary tract infection"></FilterOption></Filter><Filter label="Registry Id" name="trialRegistries" total="4"><FilterOption id="1000" count="24" label="CT.gov"></FilterOption><FilterOption id="1001" count="7" label="EudraCT"></FilterOption><FilterOption id="1021" count="1" label="NMRR"></FilterOption><FilterOption id="1030" count="1" label="RSRM CTR"></FilterOption></Filter><Filter label="Trial Reason for Discontinuation" name="trialReasonForDiscontinuation" total="1"><FilterOption id="5" count="1" label="Patient Enrollment Issues"></FilterOption></Filter><Filter label="Active Controls" name="trialActiveControls" total="3"><FilterOption id="14336" count="1" label="fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline"></FilterOption><FilterOption id="6050" count="1" label="metformin hydrochloride"></FilterOption><FilterOption id="54142" count="1" label="NAHE-001"></FilterOption></Filter><Filter label="Exclusion Criteria Index" name="trialExclusionCriteriaIndex" total="100"><FilterOption id="3839" count="2" label="Asthma - Subjects co-morbid with Respiratory Diseases/Disorders"></FilterOption><FilterOption id="17519" count="2" label="End stage renal disease - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="351" count="2" label="Hypertension - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="47" count="2" label="Hypertension - Subjects co-morbid with heart disorders/diseases - Subjects co-morbid with myocardial infarction"></FilterOption><FilterOption id="225" count="2" label="Hypertension - Subjects co-morbid with hepatobiliary disorders/diseases"></FilterOption><FilterOption id="167" count="2" label="Hypertension - Subjects co-morbid with renal disease/disorder"></FilterOption><FilterOption id="75" count="2" label="Hypertension - Subjects with Heart Failure"></FilterOption><FilterOption id="183" count="2" label="Hypertension - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="9" count="2" label="Hypertension - Subjects with Secondary Hypertension"></FilterOption><FilterOption id="18296" count="2" label="Menopause - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="18294" count="2" label="Menopause - Subjects with Protocol Specified BMI"></FilterOption><FilterOption id="836" count="2" label="Non-insulin dependent diabetes - Subjects co-morbid with Cerebrovascular Disorders/Diseases - Subjects co-morbid with transient ischemic attack"></FilterOption><FilterOption id="894" count="2" label="Non-insulin dependent diabetes - Subjects co-morbid with heart disorders/diseases - Subjects with coronary artery disease"></FilterOption><FilterOption id="891" count="2" label="Non-insulin dependent diabetes - Subjects co-morbid with heart disorders/diseases"></FilterOption><FilterOption id="837" count="2" label="Non-insulin dependent diabetes - Subjects co-morbid with renal disease/disorder"></FilterOption><FilterOption id="946" count="2" label="Non-insulin dependent diabetes - Subjects with History of/Scheduled to Receive Therapy"></FilterOption><FilterOption id="10248" count="2" label="Osteoporosis - Subjects co-morbid with endocrine/metabolic diseases/disorders"></FilterOption><FilterOption id="10808" count="2" label="Osteoporosis - Subjects with Co-morbid Conditions - Subjects co-morbid with bone diseases/disorders"></FilterOption><FilterOption id="3951" count="1" label="Asthma - Subjects with Asthma Exacerbations"></FilterOption><FilterOption id="20247" count="1" label="Asthma - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="20249" count="1" label="Asthma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for asthma drugs"></FilterOption><FilterOption id="3954" count="1" label="Asthma - Subjects with specific cigarette smoking activity - Smokers"></FilterOption><FilterOption id="7431" count="1" label="Bipolar disorder - Subjects co-morbid with Psychiatric Disease/Disorder - Subjects with anxiety disorders"></FilterOption><FilterOption id="7471" count="1" label="Bipolar disorder - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Hypersensitivity/Contraindication to mood stabilizers"></FilterOption><FilterOption id="7476" count="1" label="Bipolar disorder - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Subjects with hypersensitivity/contraindication to any investigational agents"></FilterOption><FilterOption id="7522" count="1" label="Bipolar disorder - Subjects with Progressive/Treatment Refractory Disease - Subjects resistant/refractory to antipsychotics"></FilterOption><FilterOption id="7520" count="1" label="Bipolar disorder - Subjects with Progressive/Treatment Refractory Disease - Subjects resistant/refractory to mood stabilizers"></FilterOption><FilterOption id="6246" count="1" label="Breast tumor - Subjects by disease severity - Metastatic/TNM Stage IV Breast Cancer"></FilterOption><FilterOption id="6302" count="1" label="Breast tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Subjects with hypersensitivity/contraindication to any investigational agents"></FilterOption><FilterOption id="17525" count="1" label="End stage renal disease - Subjects co-morbid with Endocrine/Metabolic Disorders - Subjects co-morbid with diabetes mellitus"></FilterOption><FilterOption id="17524" count="1" label="End stage renal disease - Subjects co-morbid with Endocrine/Metabolic Disorders"></FilterOption><FilterOption id="17528" count="1" label="End stage renal disease - Subjects co-morbid with Hematological/Coagulation Disorders"></FilterOption><FilterOption id="17522" count="1" label="End stage renal disease - Subjects co-morbid with hepatobiliary disorders/diseases"></FilterOption><FilterOption id="17518" count="1" label="End stage renal disease - Subjects co-morbid with neurological disorders/diseases"></FilterOption><FilterOption id="17553" count="1" label="End stage renal disease - Subjects with Contraindications to Study Procedure"></FilterOption><FilterOption id="17533" count="1" label="End stage renal disease - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="17545" count="1" label="End stage renal disease - Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy - Subjects with history of/scheduled for immunomodulators"></FilterOption><FilterOption id="17541" count="1" label="End stage renal disease - Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy"></FilterOption><FilterOption id="17551" count="1" label="End stage renal disease - Subjects with History of/Scheduled for Intervention/Surgery"></FilterOption><FilterOption id="17537" count="1" label="End stage renal disease - Subjects with History of/Scheduled for Renal Replacement Therapy - Subjects with protocol specified dialysis related criteria"></FilterOption><FilterOption id="17539" count="1" label="End stage renal disease - Subjects with History of/Scheduled for Renal Replacement Therapy - Subjects with protocol specified transplantation related criteria"></FilterOption><FilterOption id="17516" count="1" label="End stage renal disease - Subjects with Renal Function Outside of Protocol Specified Limits - Subjects with GFR outside of protocol specified limits"></FilterOption><FilterOption id="12709" count="1" label="Epilepsy - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="6479" count="1" label="Head and neck tumor - Subjects on Other Non-Chemotherapeutic Medications"></FilterOption><FilterOption id="5754" count="1" label="Head and neck tumor - Subjects with Abnormal Laboratory Findings - Subjects with abnormal hematological status"></FilterOption><FilterOption id="5752" count="1" label="Head and neck tumor - Subjects with Abnormal Laboratory Findings"></FilterOption><FilterOption id="5755" count="1" label="Head and neck tumor - Subjects with Abnormal Organ Function - Subjects with abnormal/unacceptable liver function"></FilterOption><FilterOption id="5757" count="1" label="Head and neck tumor - Subjects with Abnormal Organ Function - Subjects with abnormal/unacceptable renal function"></FilterOption><FilterOption id="5744" count="1" label="Head and neck tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="5751" count="1" label="Head and neck tumor - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="5779" count="1" label="Head and neck tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"></FilterOption><FilterOption id="5776" count="1" label="Head and neck tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Subjects with hypersensitivity/contraindication to any non-chemotherapeutic agents"></FilterOption><FilterOption id="5772" count="1" label="Head and neck tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Subjects with hypersensitivity/contraindication to chemotherapeutic agents"></FilterOption><FilterOption id="5771" count="1" label="Head and neck tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients"></FilterOption><FilterOption id="5693" count="1" label="Head and neck tumor - Subjects with Nasal Cavity and Paranasal Sinus Cancer"></FilterOption><FilterOption id="6750" count="1" label="Head and neck tumor - Subjects with Salivary Gland Cancer"></FilterOption><FilterOption id="6732" count="1" label="Head and neck tumor - Subjects with Therapy Associated Toxicity"></FilterOption><FilterOption id="2674" count="1" label="Hepatitis C virus infection - Subjects co-morbid with Endocrine/Metabolic Disorders - Subjects co-morbid with diabetes mellitus"></FilterOption><FilterOption id="2676" count="1" label="Hepatitis C virus infection - Subjects co-morbid with Endocrine/Metabolic Disorders - Subjects with thyroid dysfunction"></FilterOption><FilterOption id="2643" count="1" label="Hepatitis C virus infection - Subjects co-morbid with Hematological/Coagulation Disorders - Subjects co-morbid with anemia"></FilterOption><FilterOption id="2644" count="1" label="Hepatitis C virus infection - Subjects co-morbid with Hematological/Coagulation Disorders - Subjects with bleeding diathesis/coagulopathy"></FilterOption><FilterOption id="2647" count="1" label="Hepatitis C virus infection - Subjects co-morbid with Hematological/Coagulation Disorders - Subjects with hemoglobinopathy"></FilterOption><FilterOption id="2626" count="1" label="Hepatitis C virus infection - Subjects co-morbid with Psychiatric Disease/Disorder"></FilterOption><FilterOption id="2667" count="1" label="Hepatitis C virus infection - Subjects co-morbid with Respiratory Diseases/Disorders - Subjects co-morbid with chronic obstructive pulmonary disease"></FilterOption><FilterOption id="2635" count="1" label="Hepatitis C virus infection - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="8268" count="1" label="Hepatitis C virus infection - Subjects co-morbid with hepatobiliary disorders/diseases - Subjects with decompensated liver disease"></FilterOption><FilterOption id="2602" count="1" label="Hepatitis C virus infection - Subjects co-morbid with hepatobiliary disorders/diseases"></FilterOption><FilterOption id="2597" count="1" label="Hepatitis C virus infection - Subjects co-morbid with infections - Subjects co-morbid with HIV-1 infection"></FilterOption><FilterOption id="2598" count="1" label="Hepatitis C virus infection - Subjects co-morbid with infections - Subjects co-morbid with HIV-2 infection"></FilterOption><FilterOption id="2592" count="1" label="Hepatitis C virus infection - Subjects co-morbid with infections - Subjects co-morbid with hepatitis A virus infection"></FilterOption><FilterOption id="2593" count="1" label="Hepatitis C virus infection - Subjects co-morbid with infections - Subjects co-morbid with hepatitis B virus infection"></FilterOption><FilterOption id="5653" count="1" label="Hepatitis C virus infection - Subjects co-morbid with infections"></FilterOption><FilterOption id="2677" count="1" label="Hepatitis C virus infection - Subjects co-morbid with inflammatory disorders"></FilterOption><FilterOption id="2623" count="1" label="Hepatitis C virus infection - Subjects co-morbid with neurological disorders/diseases - Subjects co-morbid with epilepsy/seizures"></FilterOption><FilterOption id="2668" count="1" label="Hepatitis C virus infection - Subjects co-morbid with renal disease/disorder"></FilterOption><FilterOption id="2808" count="1" label="Hepatitis C virus infection - Subjects with Abnormal Laboratory Findings - Subjects with abnormal complete blood count"></FilterOption><FilterOption id="2774" count="1" label="Hepatitis C virus infection - Subjects with Abnormal Laboratory Findings - Subjects with abnormal serum alpha feto protein levels"></FilterOption><FilterOption id="2753" count="1" label="Hepatitis C virus infection - Subjects with Abnormal Laboratory Findings"></FilterOption><FilterOption id="5656" count="1" label="Hepatitis C virus infection - Subjects with Co-morbid Conditions - Subjects with extra-hepatic malignancies"></FilterOption><FilterOption id="5654" count="1" label="Hepatitis C virus infection - Subjects with Co-morbid Conditions - Subjects with ocular diseases/disorders"></FilterOption><FilterOption id="2689" count="1" label="Hepatitis C virus infection - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="5647" count="1" label="Hepatitis C virus infection - Subjects with Hepatitis C Infection - Subjects with HCV genotype 2 infection"></FilterOption><FilterOption id="5648" count="1" label="Hepatitis C virus infection - Subjects with Hepatitis C Infection - Subjects with HCV genotype 3 infection"></FilterOption><FilterOption id="5649" count="1" label="Hepatitis C virus infection - Subjects with Hepatitis C Infection - Subjects with HCV genotype 4 infection"></FilterOption><FilterOption id="5652" count="1" label="Hepatitis C virus infection - Subjects with Hepatitis C Infection - Subjects with mixed genotype infection"></FilterOption><FilterOption id="2589" count="1" label="Hepatitis C virus infection - Subjects with Hepatitis C Infection"></FilterOption><FilterOption id="2754" count="1" label="Hepatitis C virus infection - Subjects with History of/Scheduled for Organ Transplantation"></FilterOption><FilterOption id="2739" count="1" label="Hepatitis C virus infection - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Subjects with contraindications to anti-viral drugs"></FilterOption><FilterOption id="2737" count="1" label="Hepatitis C virus infection - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients"></FilterOption><FilterOption id="39" count="1" label="Hypertension - Subjects co-morbid with Cerebrovascular Disorders/Diseases - Subjects co-morbid with hypertensive encephalopathy"></FilterOption><FilterOption id="40" count="1" label="Hypertension - Subjects co-morbid with Cerebrovascular Disorders/Diseases - Subjects co-morbid with stroke"></FilterOption><FilterOption id="42" count="1" label="Hypertension - Subjects co-morbid with Cerebrovascular Disorders/Diseases - Subjects co-morbid with transient ischemic attack"></FilterOption><FilterOption id="36" count="1" label="Hypertension - Subjects co-morbid with Cerebrovascular Disorders/Diseases"></FilterOption><FilterOption id="220" count="1" label="Hypertension - Subjects co-morbid with Hematological/Coagulation Disorders"></FilterOption><FilterOption id="237" count="1" label="Hypertension - Subjects co-morbid with Psychiatric Disease/Disorder"></FilterOption><FilterOption id="231" count="1" label="Hypertension - Subjects co-morbid with Respiratory Diseases/Disorders"></FilterOption><FilterOption id="43" count="1" label="Hypertension - Subjects co-morbid with cardiovascular diseases/disorders - Subjects co-morbid with coronary artery disease"></FilterOption><FilterOption id="46" count="1" label="Hypertension - Subjects co-morbid with cardiovascular diseases/disorders - Subjects co-morbid with unstable/variant angina"></FilterOption><FilterOption id="209" count="1" label="Hypertension - Subjects co-morbid with gastrointestinal diseases/disorders"></FilterOption><FilterOption id="250" count="1" label="Hypertension - Subjects with Co-morbid Conditions - Endocrinal disorders"></FilterOption></Filter><Filter label="Trial Date Enrollment End By Month" name="trialDateEnrollmentEndByMonth" total="6"><FilterOption count="2" label="200603"></FilterOption><FilterOption count="1" label="200601"></FilterOption><FilterOption count="1" label="200606"></FilterOption><FilterOption count="1" label="200910"></FilterOption><FilterOption count="1" label="201109"></FilterOption><FilterOption count="1" label="201209"></FilterOption></Filter><Filter label="Funder Type" name="trialFunderType" total="1"><FilterOption id="CMP" count="24" label="Company"></FilterOption></Filter><Filter label="Trial Region" name="trialRegions" total="10"><FilterOption id="NSWE" count="24" label="Northern, Southern &amp; Western Europe"></FilterOption><FilterOption id="EEUR" count="11" label="Eastern Europe"></FilterOption><FilterOption id="USCA" count="10" label="US &amp; Canada"></FilterOption><FilterOption id="AUNZ" count="7" label="Australia &amp; New Zealand"></FilterOption><FilterOption id="CSAF" count="6" label="Central &amp; Southern Africa"></FilterOption><FilterOption id="SOAM" count="5" label="South America"></FilterOption><FilterOption id="CAAC" count="4" label="Central America &amp; Caribbean"></FilterOption><FilterOption id="EAPO" count="4" label="East Asia &amp; Pacific Ocean"></FilterOption><FilterOption id="MENA" count="4" label="Middle East &amp; North Africa"></FilterOption><FilterOption id="SOCA" count="3" label="Southern &amp; Central Asia"></FilterOption></Filter><Filter label="Patient Segment Index" name="trialPatientSegmentIndex" total="68"><FilterOption id="145" count="4" label="Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control"></FilterOption><FilterOption id="11612" count="3" label="Menopause - Subjects with Protocol Specified Menstrual Status - Postmenopausal Subjects"></FilterOption><FilterOption id="102" count="3" label="Non-insulin dependent diabetes - Subjects with Good Glycemic Control"></FilterOption><FilterOption id="103" count="3" label="Non-insulin dependent diabetes - Subjects with Poor/Inadequate Glycemic Control"></FilterOption><FilterOption id="11963" count="2" label="Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs"></FilterOption><FilterOption id="11960" count="2" label="Asthma - Subjects with Persistent Asthma - Subjects with mild persistent asthma"></FilterOption><FilterOption id="11961" count="2" label="Asthma - Subjects with Persistent Asthma - Subjects with moderate persistent asthma"></FilterOption><FilterOption id="11962" count="2" label="Asthma - Subjects with Persistent Asthma - Subjects with severe persistent asthma"></FilterOption><FilterOption id="3778" count="2" label="Head and neck tumor - Subjects with Specific Histological Sub-type of HNC - Subjects with squamous cell carcinoma"></FilterOption><FilterOption id="34" count="2" label="Hypertension - Subjects on Hypertensive Treatment"></FilterOption><FilterOption id="1" count="2" label="Hypertension - Subjects with Primary/Essential Hypertension"></FilterOption><FilterOption id="100" count="2" label="Non-insulin dependent diabetes - Subjects on Treatment/Requiring &gt;1 Antidiabetic Agent"></FilterOption><FilterOption id="108" count="2" label="Non-insulin dependent diabetes - Subjects with comorbid conditions - Subjects with obesity"></FilterOption><FilterOption id="7657" count="2" label="Osteoporosis - Subjects with Postmenopausal Osteoporosis"></FilterOption><FilterOption id="7654" count="2" label="Osteoporosis - Subjects with Primary Osteoporosis"></FilterOption><FilterOption id="3720" count="1" label="Asthma - Subjects with Symptomatic Disease - Subjects with acute/exacerbation of asthma"></FilterOption><FilterOption id="7290" count="1" label="Bipolar disorder - Subjects with Bipolar I Disorder"></FilterOption><FilterOption id="3931" count="1" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer"></FilterOption><FilterOption id="3932" count="1" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Progesterone receptor positive (PR+) breast cancer"></FilterOption><FilterOption id="3955" count="1" label="Breast tumor - Subjects with Resectable/Operable Breast Cancer"></FilterOption><FilterOption id="7702" count="1" label="End stage renal disease - Subjects by disease severity - Subjects with stage 5 chronic kidney disease/end stage renal disease(ESRD)"></FilterOption><FilterOption id="7708" count="1" label="End stage renal disease - Subjects with Diabetes/Diabetic Nephropathy"></FilterOption><FilterOption id="7699" count="1" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 2 chronic kidney disease"></FilterOption><FilterOption id="7700" count="1" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 3 chronic kidney disease"></FilterOption><FilterOption id="7701" count="1" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 4 chronic kidney disease"></FilterOption><FilterOption id="7755" count="1" label="End stage renal disease - Subjects with Other Cardiac Disease/Associated Nephropathy"></FilterOption><FilterOption id="10308" count="1" label="Epilepsy - Subjects with Partial Seizures - Subjects with complex partial seizures"></FilterOption><FilterOption id="10309" count="1" label="Epilepsy - Subjects with Partial Seizures - Subjects with partial seizures with secondary generalization"></FilterOption><FilterOption id="10307" count="1" label="Epilepsy - Subjects with Partial Seizures - Subjects with simple partial seizures"></FilterOption><FilterOption id="3774" count="1" label="Head and neck tumor - Subjects with Advanced/Metastatic Head and Neck Cancer"></FilterOption><FilterOption id="3771" count="1" label="Head and neck tumor - Subjects with Laryngeal Cancer - Subjects with glottic laryngeal cancer"></FilterOption><FilterOption id="3772" count="1" label="Head and neck tumor - Subjects with Laryngeal Cancer - Subjects with subglottic laryngeal cancer"></FilterOption><FilterOption id="3770" count="1" label="Head and neck tumor - Subjects with Laryngeal Cancer - Subjects with supraglottic laryngeal cancer"></FilterOption><FilterOption id="7278" count="1" label="Head and neck tumor - Subjects with Oral Cancer"></FilterOption><FilterOption id="7284" count="1" label="Head and neck tumor - Subjects with Pharyngeal Cancer - Subjects with hypopharyngeal cancer"></FilterOption><FilterOption id="7283" count="1" label="Head and neck tumor - Subjects with Pharyngeal Cancer - Subjects with oropharyngeal cancer"></FilterOption><FilterOption id="3804" count="1" label="Head and neck tumor - Subjects with Relapsed/Recurrent Head and Neck Cancer"></FilterOption><FilterOption id="10293" count="1" label="Head and neck tumor - Subjects with TNM Stage IV Head and Neck Cancer - Subjects with TNM stage IVc HNC"></FilterOption><FilterOption id="3800" count="1" label="Head and neck tumor - Subjects with Treatment Resistant Disease - Subjects with chemotherapy resistant disease"></FilterOption><FilterOption id="3799" count="1" label="Head and neck tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="7487" count="1" label="Hepatitis C virus infection - Subjects Infected with HCV Genotype 1"></FilterOption><FilterOption id="461" count="1" label="Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection"></FilterOption><FilterOption id="490" count="1" label="Hepatitis C virus infection - Subjects with Prior Hepatitis C Therapy"></FilterOption><FilterOption id="491" count="1" label="Hepatitis C virus infection - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="6" count="1" label="Hypertension - Subjects with Primary/Essential Hypertension - Subjects with stage 2 (JNC 6) hypertension"></FilterOption><FilterOption id="37" count="1" label="Hypertension - Subjects with Primary/Essential Hypertension - Subjects with stage 3 (JNC 6) hypertension"></FilterOption><FilterOption id="11" count="1" label="Hypertension - Subjects with Refractory/Resistant/Uncontrolled Hypertension"></FilterOption><FilterOption id="14" count="1" label="Hypertension - Subjects with comorbid conditions"></FilterOption><FilterOption id="33" count="1" label="Hypertension - Treatment Naive Subjects"></FilterOption><FilterOption id="10967" count="1" label="Hypopituitarism - Subjects with Growth hormone (GH) Deficiency"></FilterOption><FilterOption id="11034" count="1" label="Insulin resistance - Insulin Resistance in Metabolic Diseases Subjects - Subjects with metabolic syndrome"></FilterOption><FilterOption id="11319" count="1" label="Lipid metabolism disorder - Subjects with Risk Factors for Coronary Heart Disease(CHD)"></FilterOption><FilterOption id="10295" count="1" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer"></FilterOption><FilterOption id="3634" count="1" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer"></FilterOption><FilterOption id="3623" count="1" label="Lung tumor - Subjects with Advanced Stage Lung Cancer"></FilterOption><FilterOption id="3617" count="1" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"></FilterOption><FilterOption id="11622" count="1" label="Menopause - Subjects with Bone Disorders"></FilterOption><FilterOption id="11624" count="1" label="Menopause - Subjects with History of/Scheduled for drug Therapy"></FilterOption><FilterOption id="11614" count="1" label="Menopause - Subjects with Premature Menopause - Subjects with surgical menopause"></FilterOption><FilterOption id="11621" count="1" label="Menopause - Subjects with comorbid conditions - Subjects with Cancer"></FilterOption><FilterOption id="11623" count="1" label="Menopause - Subjects with history/Scheduled for Hormonal Therapy"></FilterOption><FilterOption id="9603" count="1" label="Metabolic syndrome X - Hypertensive Subjects with Metabolic Syndrome"></FilterOption><FilterOption id="170" count="1" label="Non-insulin dependent diabetes - Diabetes Mellitus Subjects with CVD Risk Factors"></FilterOption><FilterOption id="99" count="1" label="Non-insulin dependent diabetes - Subjects on Monotherapy - Subjects on other single antidiabetic agent"></FilterOption><FilterOption id="104" count="1" label="Non-insulin dependent diabetes - Subjects with comorbid conditions"></FilterOption><FilterOption id="7665" count="1" label="Osteoporosis - Subjects at risk of developing disease - Women at risk of developing osteoporosis"></FilterOption><FilterOption id="3581" count="1" label="Prostate tumor - Subjects with Hormone Sensitive Prostate Cancer"></FilterOption><FilterOption id="8169" count="1" label="Urinary tract infection - Subjects with Complicated Urinary Tract Infection"></FilterOption></Filter><Filter label="Primary Completion Filter by Month" name="trialPrimaryCompletionDateByMonth" total="14"><FilterOption count="2" label="200606"></FilterOption><FilterOption count="2" label="200803"></FilterOption><FilterOption count="1" label="200508"></FilterOption><FilterOption count="1" label="200511"></FilterOption><FilterOption count="1" label="200603"></FilterOption><FilterOption count="1" label="200607"></FilterOption><FilterOption count="1" label="200702"></FilterOption><FilterOption count="1" label="200707"></FilterOption><FilterOption count="1" label="200709"></FilterOption><FilterOption count="1" label="200801"></FilterOption><FilterOption count="1" label="201008"></FilterOption><FilterOption count="1" label="201207"></FilterOption><FilterOption count="1" label="201210"></FilterOption><FilterOption count="1" label="201212"></FilterOption></Filter><Filter label="Trial Country" name="trialCountries" total="50"><FilterOption id="ES" count="24" label="Spain"></FilterOption><FilterOption id="FR" count="10" label="France"></FilterOption><FilterOption id="CA" count="8" label="Canada"></FilterOption><FilterOption id="DE" count="8" label="Germany"></FilterOption><FilterOption id="GB" count="8" label="UK"></FilterOption><FilterOption id="US" count="8" label="US"></FilterOption><FilterOption id="AU" count="7" label="Australia"></FilterOption><FilterOption id="IT" count="7" label="Italy"></FilterOption><FilterOption id="RU" count="7" label="Russian Federation"></FilterOption><FilterOption id="NL" count="6" label="Netherlands"></FilterOption><FilterOption id="NO" count="6" label="Norway"></FilterOption><FilterOption id="ZA" count="6" label="South Africa"></FilterOption><FilterOption id="AR" count="5" label="Argentina"></FilterOption><FilterOption id="BE" count="5" label="Belgium"></FilterOption><FilterOption id="BR" count="5" label="Brazil"></FilterOption><FilterOption id="PL" count="5" label="Poland"></FilterOption><FilterOption id="SE" count="5" label="Sweden"></FilterOption><FilterOption id="CZ" count="4" label="Czech Republic"></FilterOption><FilterOption id="GR" count="4" label="Greece"></FilterOption><FilterOption id="MX" count="4" label="Mexico"></FilterOption><FilterOption id="BG" count="3" label="Bulgaria"></FilterOption><FilterOption id="FI" count="3" label="Finland"></FilterOption><FilterOption id="HU" count="3" label="Hungary"></FilterOption><FilterOption id="IN" count="3" label="India"></FilterOption><FilterOption id="MY" count="3" label="Malaysia"></FilterOption><FilterOption id="EE" count="2" label="Estonia"></FilterOption><FilterOption id="HK" count="2" label="Hong Kong"></FilterOption><FilterOption id="PH" count="2" label="Philippines"></FilterOption><FilterOption id="PR" count="2" label="Puerto Rico"></FilterOption><FilterOption id="TH" count="2" label="Thailand"></FilterOption><FilterOption id="TR" count="2" label="Turkey"></FilterOption><FilterOption id="AT" count="1" label="Austria"></FilterOption><FilterOption id="CN" count="1" label="China"></FilterOption><FilterOption id="HR" count="1" label="Croatia"></FilterOption><FilterOption id="DK" count="1" label="Denmark"></FilterOption><FilterOption id="IS" count="1" label="Iceland"></FilterOption><FilterOption id="ID" count="1" label="Indonesia"></FilterOption><FilterOption id="IE" count="1" label="Ireland"></FilterOption><FilterOption id="IL" count="1" label="Israel"></FilterOption><FilterOption id="LV" count="1" label="Latvia"></FilterOption><FilterOption id="LB" count="1" label="Lebanon"></FilterOption><FilterOption id="LT" count="1" label="Lithuania"></FilterOption><FilterOption id="PE" count="1" label="Peru"></FilterOption><FilterOption id="PT" count="1" label="Portugal"></FilterOption><FilterOption id="SG" count="1" label="Singapore"></FilterOption><FilterOption id="SK" count="1" label="Slovakia"></FilterOption><FilterOption id="SI" count="1" label="Slovenia"></FilterOption><FilterOption id="CH" count="1" label="Switzerland"></FilterOption><FilterOption id="UA" count="1" label="Ukraine"></FilterOption><FilterOption id="VN" count="1" label="Vietnam"></FilterOption></Filter><Filter label="Trial Patient Selection" name="trialTermsPatientSelection" total="10"><FilterOption id="EAAAD" count="23" label="Aged Adults (65-79 yrs)"></FilterOption><FilterOption id="EAMAA" count="23" label="Middle-aged Adults (45-64 yrs)"></FilterOption><FilterOption id="EAELD" count="19" label="Elderly Adults (80 and over)"></FilterOption><FilterOption id="EAYAD" count="19" label="Young Adults (18-44 yrs)"></FilterOption><FilterOption id="EAADL" count="3" label="Adolescents (13-17 yrs)"></FilterOption><FilterOption id="EGFEM" count="3" label="Female"></FilterOption><FilterOption id="EACHI" count="2" label="Children (6-12 yrs)"></FilterOption><FilterOption id="ECEUR" count="2" label="European Ancestry"></FilterOption><FilterOption id="EGMAL" count="1" label="Male"></FilterOption><FilterOption id="EAPRE" count="1" label="Preschool Children (2-5 yrs)"></FilterOption></Filter><Filter label="Trial Terms Design" name="trialTermsDesign" total="20"><FilterOption id="SSTINV" count="16" label="Interventional"></FilterOption><FilterOption id="SISPRL" count="15" label="Parallel Assignment"></FilterOption><FilterOption id="SIARND" count="15" label="Randomized"></FilterOption><FilterOption id="SIPTRE" count="14" label="Treatment"></FilterOption><FilterOption id="SIMMBD" count="11" label="Multiple Blind"></FilterOption><FilterOption id="SSTOBS" count="8" label="Observational"></FilterOption><FilterOption id="SICACT" count="6" label="Active Control"></FilterOption><FilterOption id="SICPLC" count="6" label="Placebo Control"></FilterOption><FilterOption id="SIMOPN" count="5" label="Open Label"></FilterOption><FilterOption id="SOTPRO" count="4" label="Prospective"></FilterOption><FilterOption id="SOSCOH" count="3" label="Cohort"></FilterOption><FilterOption id="SODXSC" count="2" label="Cross-sectional"></FilterOption><FilterOption id="SICDSC" count="2" label="Dose Comparison"></FilterOption><FilterOption id="SIPPRE" count="2" label="Prevention"></FilterOption><FilterOption id="SOTRET" count="2" label="Retrospective"></FilterOption><FilterOption id="SOSDEF" count="1" label="Defined Population"></FilterOption><FilterOption id="SODLNG" count="1" label="Longitudinal"></FilterOption><FilterOption id="SICNOC" count="1" label="No Control"></FilterOption><FilterOption id="SIANON" count="1" label="Non-Randomized"></FilterOption><FilterOption id="SISSNG" count="1" label="Single Group Assignment"></FilterOption></Filter><Filter label="Trial Source" name="trialSources" total="2"><FilterOption id="CTGOVOTHERS" count="18" label="ClinicalTrials.gov and others"></FilterOption><FilterOption id="CTGOV" count="6" label="ClinicalTrials.gov only"></FilterOption></Filter><Filter label="Trial Actions Secondary Interventions Primary" name="trialActionsSecondaryInterventionsPrimary" total="32"><FilterOption id="1545" count="7" label="Anticancer"></FilterOption><FilterOption id="399" count="4" label="Hypoglycemic agent"></FilterOption><FilterOption id="2953" count="3" label="Anti-inflammatory"></FilterOption><FilterOption id="62255" count="2" label="Anticancer protein kinase inhibitor"></FilterOption><FilterOption id="70" count="2" label="Anticonvulsant agent"></FilterOption><FilterOption id="72" count="2" label="Antihyperlipidemic agent"></FilterOption><FilterOption id="2657" count="2" label="Antihypertensive"></FilterOption><FilterOption id="89" count="2" label="Bone resorption inhibitor"></FilterOption><FilterOption id="646" count="2" label="Bronchodilator"></FilterOption><FilterOption id="3189" count="2" label="Corticosteroid agonist"></FilterOption><FilterOption id="2954" count="2" label="Steroidal anti-inflammatory"></FilterOption><FilterOption id="38200" count="1" label="Acid pump inhibitor antiulcerant product"></FilterOption><FilterOption id="2970" count="1" label="Anti-emetic"></FilterOption><FilterOption id="449" count="1" label="Antiarrhythmic agent"></FilterOption><FilterOption id="1594" count="1" label="Antibacterial"></FilterOption><FilterOption id="2941" count="1" label="Antidepressant"></FilterOption><FilterOption id="2943" count="1" label="Antipsychotic"></FilterOption><FilterOption id="991" count="1" label="Antiviral"></FilterOption><FilterOption id="104" count="1" label="Bacterial cell wall synthesis inhibitor"></FilterOption><FilterOption id="2659" count="1" label="Cardioprotectant"></FilterOption><FilterOption id="767" count="1" label="Cell cycle inhibitor"></FilterOption><FilterOption id="137" count="1" label="Diuretic agent"></FilterOption><FilterOption id="1332" count="1" label="Gastrointestinal system agent"></FilterOption><FilterOption id="3246" count="1" label="Insulin release stimulator"></FilterOption><FilterOption id="2575" count="1" label="Microtubule inhibitor"></FilterOption><FilterOption id="1129" count="1" label="Non-steroid hormone receptor antagonist"></FilterOption><FilterOption id="12596" count="1" label="Osteoclast inhibitor"></FilterOption><FilterOption id="1536" count="1" label="Penicillin"></FilterOption><FilterOption id="38205" count="1" label="Sulphonylurea antidiabetic product"></FilterOption><FilterOption id="15187" count="1" label="Systemic dermatological antibacterial product"></FilterOption><FilterOption id="15190" count="1" label="Systemic dermatological antiviral product"></FilterOption><FilterOption id="388" count="1" label="Vasodilator"></FilterOption></Filter><Filter label="Trial Endpoint Achieved" name="trialEndpointsAchieved" total="3"><FilterOption id="UNSPECIFIED" count="12" label="Unspecified"></FilterOption><FilterOption id="YES" count="5" label="Yes"></FilterOption><FilterOption id="NO" count="1" label="No"></FilterOption></Filter><Filter label="Endpoint Index Secondary" name="trialEndpointIndexSecondary" total="100"><FilterOption id="1345" count="3" label="Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose"></FilterOption><FilterOption id="7312" count="2" label="Head and neck tumor - Assessment of adverse events"></FilterOption><FilterOption id="176" count="2" label="Hypertension - Assessment of Inflammatory &amp; Oxidative Stress Markers - High-sensitivity C-reactive protein (hsCRP)"></FilterOption><FilterOption id="23553" count="2" label="Menopause - Assessment of Bone - Assessment by Bone mineral density (BMD)"></FilterOption><FilterOption id="1503" count="2" label="Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of body weight"></FilterOption><FilterOption id="1626" count="2" label="Non-insulin dependent diabetes - Assessment of Adverse Events"></FilterOption><FilterOption id="1429" count="2" label="Non-insulin dependent diabetes - Assessment of Inflammatory &amp; Oxidative Stress Markers - High-sensitivity C-reactive protein (hsCRP)"></FilterOption><FilterOption id="1452" count="2" label="Non-insulin dependent diabetes - Assessment of lipid profiles - Assessment of Total Cholesterol"></FilterOption><FilterOption id="1454" count="2" label="Non-insulin dependent diabetes - Assessment of lipid profiles - HDL-C (High-density lipoprotein cholesterol)"></FilterOption><FilterOption id="1455" count="2" label="Non-insulin dependent diabetes - Assessment of lipid profiles - LDL-C (Low-density lipoprotein cholesterol)"></FilterOption><FilterOption id="1453" count="2" label="Non-insulin dependent diabetes - Assessment of lipid profiles - Triglyceride levels (TG)"></FilterOption><FilterOption id="1451" count="2" label="Non-insulin dependent diabetes - Assessment of lipid profiles"></FilterOption><FilterOption id="13771" count="2" label="Osteoporosis - Assessment of Bone - Assessment by Bone mineral density (BMD)"></FilterOption><FilterOption id="5984" count="1" label="Asthma - Assessment of Exacerbations - Exacerbation requiring hospitalization"></FilterOption><FilterOption id="5985" count="1" label="Asthma - Assessment of Exacerbations - Number/rate/frequency/duration of exacerbation"></FilterOption><FilterOption id="5986" count="1" label="Asthma - Assessment of Exacerbations - Severity of exacerbation"></FilterOption><FilterOption id="5983" count="1" label="Asthma - Assessment of Exacerbations"></FilterOption><FilterOption id="5939" count="1" label="Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1)"></FilterOption><FilterOption id="6083" count="1" label="Asthma - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="6082" count="1" label="Asthma - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="6076" count="1" label="Asthma - Assessment of Therapy Related Outcomes - Asthma control"></FilterOption><FilterOption id="6078" count="1" label="Asthma - Assessment of Therapy Related Outcomes - Efficacy"></FilterOption><FilterOption id="6068" count="1" label="Asthma - Assessment of use of Rescue Medication - Duration of medication use"></FilterOption><FilterOption id="6069" count="1" label="Asthma - Assessment of use of Rescue Medication - Frequency/rate of medication use"></FilterOption><FilterOption id="6064" count="1" label="Asthma - Assessment of use of Rescue Medication"></FilterOption><FilterOption id="37466" count="1" label="Asthma - Health Economic Assessments - Assessment of direct cost"></FilterOption><FilterOption id="37469" count="1" label="Asthma - Health Economic Assessments - Health Services Utilization"></FilterOption><FilterOption id="6111" count="1" label="Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma control questionnaire (ACQ)"></FilterOption><FilterOption id="6108" count="1" label="Asthma - Patient Reported Outcomes/Quality of Life Assessments"></FilterOption><FilterOption id="9923" count="1" label="Bipolar disorder - Assessment of Bipolar Disorder Symptoms - Assessment of mania"></FilterOption><FilterOption id="9922" count="1" label="Bipolar disorder - Assessment of Co-morbidity - Assessment of depression"></FilterOption><FilterOption id="10037" count="1" label="Bipolar disorder - Assessment of Disease Relapse/Recurrence - Assessment of time to recurrence"></FilterOption><FilterOption id="8983" count="1" label="Breast tumor - Assessment of Biopsy/Cytology/Histology"></FilterOption><FilterOption id="9011" count="1" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of systemic toxicity"></FilterOption><FilterOption id="8998" count="1" label="Breast tumor - Assessment of adverse events"></FilterOption><FilterOption id="9315" count="1" label="Breast tumor - Imaging/Radiological Assessments - Assessment by ultrasonography"></FilterOption><FilterOption id="22532" count="1" label="End stage renal disease - Assessment of Biomarkers - Assessment of other inflammatory/oxidative stress markers"></FilterOption><FilterOption id="22506" count="1" label="End stage renal disease - Assessment of Glomerular Filtration Rate (GFR) - Assessment of Estimated Glomerular Filtration Rate(eGFR)/Creatinine Clearance(CCr/CrCl/CLcr)"></FilterOption><FilterOption id="22596" count="1" label="End stage renal disease - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="22559" count="1" label="End stage renal disease - Assessment of Nutritional Status"></FilterOption><FilterOption id="22507" count="1" label="End stage renal disease - Assessment of Serum Creatinine"></FilterOption><FilterOption id="22511" count="1" label="End stage renal disease - Assessment of Urinary Protein Excretion/Proteinuria - Assessment of proteinuria/albuminuria/macroalbuminuria"></FilterOption><FilterOption id="7324" count="1" label="Head and neck tumor - Assessment of Chemotherapy Induced Toxicity"></FilterOption><FilterOption id="7275" count="1" label="Head and neck tumor - Assessment of Clinical Response"></FilterOption><FilterOption id="7292" count="1" label="Head and neck tumor - Assessment of Markers of Tumor Growth and Progression"></FilterOption><FilterOption id="7244" count="1" label="Head and neck tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="7256" count="1" label="Head and neck tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="7264" count="1" label="Head and neck tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="7263" count="1" label="Head and neck tumor - Assessment of Response Rates (RR)"></FilterOption><FilterOption id="7327" count="1" label="Head and neck tumor - Assessment of Safety and Tolerability - Assessment of chemotherapy induced nausea and vomiting"></FilterOption><FilterOption id="7313" count="1" label="Head and neck tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="7311" count="1" label="Head and neck tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="7299" count="1" label="Head and neck tumor - Patient Reported Outcomes/Quality of Life Assessments"></FilterOption><FilterOption id="9434" count="1" label="Hepatitis C virus infection - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="78" count="1" label="Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - 24-hour mean ADBP"></FilterOption><FilterOption id="82" count="1" label="Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Day-time mean ADBP"></FilterOption><FilterOption id="86" count="1" label="Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Night-time mean ADBP"></FilterOption><FilterOption id="2" count="1" label="Hypertension - Assessment of Blood Pressure (BP) - BP control rate"></FilterOption><FilterOption id="3" count="1" label="Hypertension - Assessment of Blood Pressure (BP) - BP response rate"></FilterOption><FilterOption id="1" count="1" label="Hypertension - Assessment of Blood Pressure (BP)"></FilterOption><FilterOption id="40" count="1" label="Hypertension - Assessment of Diastolic Blood Pressure (DBP) - Seated DBP"></FilterOption><FilterOption id="44" count="1" label="Hypertension - Assessment of Diastolic Blood Pressure (DBP) - Trough DBP"></FilterOption><FilterOption id="245" count="1" label="Hypertension - Assessment of Glomerular Filtration Rate (GFR)"></FilterOption><FilterOption id="221" count="1" label="Hypertension - Assessment of Insulin Sensitivity - Quantitative insulin sensitivity check index (QUICKI)"></FilterOption><FilterOption id="211" count="1" label="Hypertension - Assessment of Insulin Sensitivity"></FilterOption><FilterOption id="136" count="1" label="Hypertension - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="468" count="1" label="Hypertension - Assessment of Renal Function - Microalbuminuria level"></FilterOption><FilterOption id="258" count="1" label="Hypertension - Assessment of Renal Function - Serum uric acid"></FilterOption><FilterOption id="252" count="1" label="Hypertension - Assessment of Renal Function - Urinary albumin to creatinine ratio (UACR)"></FilterOption><FilterOption id="246" count="1" label="Hypertension - Assessment of Serum Creatinine"></FilterOption><FilterOption id="25" count="1" label="Hypertension - Assessment of Systolic Blood Pressure (SBP) - Seated SBP"></FilterOption><FilterOption id="29" count="1" label="Hypertension - Assessment of Systolic Blood Pressure (SBP) - Trough SBP"></FilterOption><FilterOption id="232" count="1" label="Hypertension - Assessment of lipid profiles - Assessment of ApoA"></FilterOption><FilterOption id="233" count="1" label="Hypertension - Assessment of lipid profiles - Assessment of apolipoprotein B (Apo B)"></FilterOption><FilterOption id="224" count="1" label="Hypertension - Assessment of lipid profiles - Triglyceride levels (TG)"></FilterOption><FilterOption id="472" count="1" label="Hypertension - Assessment of use of Rescue Medication"></FilterOption><FilterOption id="24847" count="1" label="Hypopituitarism - Anthropometric Assessments - Assessment of BMI"></FilterOption><FilterOption id="24849" count="1" label="Hypopituitarism - Anthropometric Assessments - Assessment of height"></FilterOption><FilterOption id="24855" count="1" label="Hypopituitarism - Anthropometric Assessments - Assessment of weight"></FilterOption><FilterOption id="23299" count="1" label="Insulin resistance - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C reactive protein (CRP)"></FilterOption><FilterOption id="23381" count="1" label="Insulin resistance - Assessment of Renal Function"></FilterOption><FilterOption id="23065" count="1" label="Lipid metabolism disorder - Assessment of Cardiovascular Risk Factors"></FilterOption><FilterOption id="23122" count="1" label="Lipid metabolism disorder - Assessment of Inflammatory &amp; Oxidative Stress Markers - High-sensitivity C-reactive protein (hsCRP)"></FilterOption><FilterOption id="23079" count="1" label="Lipid metabolism disorder - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="23096" count="1" label="Lipid metabolism disorder - Assessment of Renal Function - Assessment of creatinine"></FilterOption><FilterOption id="23094" count="1" label="Lipid metabolism disorder - Assessment of Renal Function - Assessment of eGFR"></FilterOption><FilterOption id="23091" count="1" label="Lipid metabolism disorder - Assessment of Renal Function"></FilterOption><FilterOption id="23187" count="1" label="Lipid metabolism disorder - Assessment of Urine (Urinalysis) - Uric acid analysis"></FilterOption><FilterOption id="23054" count="1" label="Lipid metabolism disorder - Assessment of lipid profiles - Assessment of Apo A"></FilterOption><FilterOption id="23056" count="1" label="Lipid metabolism disorder - Assessment of lipid profiles - Assessment of apolipoprotein B"></FilterOption><FilterOption id="32185" count="1" label="Lipid metabolism disorder - Patient Reported Outcomes/Quality of Life Assessments - Medication adherence questionnaires"></FilterOption><FilterOption id="8588" count="1" label="Lung tumor - Assessment of Biopsy/Cytology/Histology"></FilterOption><FilterOption id="8608" count="1" label="Lung tumor - Assessment of Oncogenes/Oncoproteins - Assessment of EGFR mutation/ amplification status"></FilterOption><FilterOption id="23556" count="1" label="Menopause - Assessment of Biomarkers - Assessment of bone markers"></FilterOption><FilterOption id="23554" count="1" label="Menopause - Assessment of Bone - Assessment of bone fracture"></FilterOption><FilterOption id="23531" count="1" label="Menopause - Assessment of Endometrium"></FilterOption><FilterOption id="23564" count="1" label="Menopause - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="23562" count="1" label="Menopause - Assessment of Therapy Related Outcomes - Assessment of response to cancer therapy"></FilterOption><FilterOption id="21014" count="1" label="Metabolic syndrome X - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C reactive protein (CRP)"></FilterOption><FilterOption id="21031" count="1" label="Metabolic syndrome X - Assessment of Renal Function - Assessment of creatinine"></FilterOption></Filter><Filter label="Biomarker" name="trialBiomarkerNames" total="38"><FilterOption id="133" count="5" label="Total cholesterol"></FilterOption><FilterOption id="1735" count="4" label="Glucose"></FilterOption><FilterOption id="289" count="4" label="Hemoglobin A, glycosylated"></FilterOption><FilterOption id="153" count="4" label="High-density lipoprotein cholesterol"></FilterOption><FilterOption id="2586" count="3" label="Blood pressure"></FilterOption><FilterOption id="46" count="3" label="C-reactive protein"></FilterOption><FilterOption id="152" count="3" label="Low-density lipoprotein cholesterol"></FilterOption><FilterOption id="172" count="2" label="Adiponectin"></FilterOption><FilterOption id="113" count="2" label="Body Mass Index"></FilterOption><FilterOption id="213" count="2" label="Creatinine"></FilterOption><FilterOption id="332" count="2" label="Diastolic blood pressure"></FilterOption><FilterOption id="8" count="2" label="Epidermal growth factor receptor"></FilterOption><FilterOption id="7895" count="2" label="Estimated glomerular filtration rate"></FilterOption><FilterOption id="303" count="2" label="Leptin"></FilterOption><FilterOption id="330" count="2" label="Systolic blood pressure"></FilterOption><FilterOption id="12058" count="2" label="Total body mass"></FilterOption><FilterOption id="217" count="2" label="Triglycerides"></FilterOption><FilterOption id="450" count="1" label="Alkaline phosphatase, tissue-nonspecific isozyme"></FilterOption><FilterOption id="214" count="1" label="Apolipoprotein A-I"></FilterOption><FilterOption id="215" count="1" label="Apolipoprotein B-100"></FilterOption><FilterOption id="434" count="1" label="Appetite regulating hormone"></FilterOption><FilterOption id="17697" count="1" label="Body height"></FilterOption><FilterOption id="130" count="1" label="C-C motif chemokine 2"></FilterOption><FilterOption id="483" count="1" label="Collagen type I trimeric cross-linked peptide"></FilterOption><FilterOption id="7938" count="1" label="Conserved oligomeric Golgi complex subunit 2"></FilterOption><FilterOption id="2713" count="1" label="Forced expiratory volume"></FilterOption><FilterOption id="3" count="1" label="HER2"></FilterOption><FilterOption id="9815" count="1" label="Hip circumference"></FilterOption><FilterOption id="808" count="1" label="Insulin"></FilterOption><FilterOption id="379" count="1" label="Insulin-like growth factor 1"></FilterOption><FilterOption id="176" count="1" label="Interleukin-6"></FilterOption><FilterOption id="14767" count="1" label="Lipids"></FilterOption><FilterOption id="2053" count="1" label="Non-high density lipoprotein cholesterol"></FilterOption><FilterOption id="428" count="1" label="Resistin"></FilterOption><FilterOption id="288" count="1" label="Uric acid"></FilterOption><FilterOption id="4139" count="1" label="Urinary albumin excretion rate"></FilterOption><FilterOption id="1183" count="1" label="Urinary albumin to creatinine ratio"></FilterOption><FilterOption id="418" count="1" label="Waist circumference"></FilterOption></Filter><Filter label="Trial Terms Endpoint" name="trialTermsEndpoint" total="4"><FilterOption id="SIEEFC" count="16" label="Efficacy"></FilterOption><FilterOption id="SIESFT" count="15" label="Safety"></FilterOption><FilterOption id="SIEPCD" count="3" label="Pharmacodynamics"></FilterOption><FilterOption id="SIEPCK" count="2" label="Pharmacokinetics"></FilterOption></Filter><Filter label="Trial Interventions Primary In Regimen Name Display" name="trialInterventionsPrimaryInRegimenNameDisplay" total="8"><FilterOption id="2953" count="1" label="docetaxel"></FilterOption><FilterOption id="11603" count="1" label="gefitinib"></FilterOption><FilterOption id="46890" count="1" label="glibenclamide"></FilterOption><FilterOption id="45998" count="1" label="interferon alfa-2b"></FilterOption><FilterOption id="33451" count="1" label="muraglitazar"></FilterOption><FilterOption id="54142" count="1" label="NAHE-001"></FilterOption><FilterOption id="3317" count="1" label="quetiapine IR"></FilterOption><FilterOption id="5265" count="1" label="valproic acid (oral extended-release), Sanofi"></FilterOption></Filter><Filter label="Trial Document Source" name="trialDocumentSource" total="5"><FilterOption id="SERIAL" count="12" label="Serial Publications"></FilterOption><FilterOption id="PR" count="6" label="Press Releases"></FilterOption><FilterOption id="OTHER" count="4" label="Other Publications"></FilterOption><FilterOption id="CONFERENCE" count="2" label="Conference Reports"></FilterOption><FilterOption id="CORPORATE" count="2" label="Corporate Publications"></FilterOption></Filter><Filter label="Trial Interventions Primary Alone Name Display" name="trialInterventionsPrimaryAloneNameDisplay" total="16"><FilterOption id="30712" count="2" label="budesonide + formoterol fumarate, AstraZeneca"></FilterOption><FilterOption id="3321" count="1" label="anastrozole"></FilterOption><FilterOption id="58762" count="1" label="empagliflozin"></FilterOption><FilterOption id="16026" count="1" label="esomeprazole"></FilterOption><FilterOption id="13572" count="1" label="exenatide"></FilterOption><FilterOption id="11603" count="1" label="gefitinib"></FilterOption><FilterOption id="45998" count="1" label="interferon alfa-2b"></FilterOption><FilterOption id="4469" count="1" label="irbesartan"></FilterOption><FilterOption id="5665" count="1" label="levetiracetam (oral), UCB"></FilterOption><FilterOption id="33451" count="1" label="muraglitazar"></FilterOption><FilterOption id="46939" count="1" label="olmesartan medoxomil + hydrochlorothiazide (hypertension), Sankyo"></FilterOption><FilterOption id="8946" count="1" label="olmesartan medoxomil"></FilterOption><FilterOption id="29446" count="1" label="piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho"></FilterOption><FilterOption id="6681" count="1" label="raloxifene"></FilterOption><FilterOption id="4234" count="1" label="risedronate sodium"></FilterOption><FilterOption id="4433" count="1" label="somatropin, Horizon Pharma"></FilterOption></Filter><Filter label="Trial Interventions Control In Regimen Name Display" name="trialInterventionsControlInRegimenNameDisplay" total="1"><FilterOption id="14336" count="1" label="fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline"></FilterOption></Filter><Filter label="Trial Category" name="trialCategory" total="7"><FilterOption id="4" count="17" label="Small molecule"></FilterOption><FilterOption id="3" count="3" label="Biological"></FilterOption><FilterOption id="17" count="1" label="Biomarker identification"></FilterOption><FilterOption id="14" count="1" label="Diagnostic"></FilterOption><FilterOption id="11" count="1" label="Dietary supplement"></FilterOption><FilterOption id="9" count="1" label="Medical procedure"></FilterOption><FilterOption id="18" count="1" label="Pathophysiology"></FilterOption></Filter><Filter label="Trial Outcome Available" name="trialOutcomesAvailable" total="2"><FilterOption id="YES" count="18" label="Yes"></FilterOption><FilterOption id="NO" count="6" label="No"></FilterOption></Filter><Filter label="Trial Actions Primary Interventions Primary" name="trialActionsPrimaryInterventionsPrimary" total="22"><FilterOption id="788" count="2" label="Angiotensin II AT-1 receptor antagonist"></FilterOption><FilterOption id="40" count="2" label="Beta 2 adrenoceptor agonist"></FilterOption><FilterOption id="3754" count="2" label="EGFR family tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="1919" count="2" label="Insulin sensitizer"></FilterOption><FilterOption id="3033" count="2" label="PPAR alpha agonist"></FilterOption><FilterOption id="2480" count="2" label="PPAR gamma agonist"></FilterOption><FilterOption id="13" count="1" label="5-HT 2 receptor antagonist"></FilterOption><FilterOption id="64" count="1" label="Angiotensin II receptor antagonist"></FilterOption><FilterOption id="76" count="1" label="Aromatase inhibitor"></FilterOption><FilterOption id="86" count="1" label="Beta lactamase inhibitor"></FilterOption><FilterOption id="7735" count="1" label="CDKN1A gene modulator"></FilterOption><FilterOption id="150" count="1" label="Dopamine D2 receptor antagonist"></FilterOption><FilterOption id="846" count="1" label="Estrogen receptor modulator"></FilterOption><FilterOption id="173" count="1" label="GABA receptor agonist"></FilterOption><FilterOption id="2585" count="1" label="Glucagon-like peptide 1 receptor agonist"></FilterOption><FilterOption id="21072" count="1" label="Growth hormone ligand"></FilterOption><FilterOption id="208" count="1" label="H+ K+ ATPase inhibitor"></FilterOption><FilterOption id="51174" count="1" label="Interferon alpha 5 ligand"></FilterOption><FilterOption id="917" count="1" label="Interferon alpha ligand modulator"></FilterOption><FilterOption id="498" count="1" label="Sodium channel inhibitor"></FilterOption><FilterOption id="4020" count="1" label="Sodium glucose transporter-2 inhibitor"></FilterOption><FilterOption id="15477" count="1" label="Synaptic vesicle glycoprotein 2A modulator"></FilterOption></Filter><Filter label="Trial Company Collaborator" name="trialCompaniesCollaborator" total="3"><FilterOption id="17810" count="2" label="Eli Lilly &amp; Co"></FilterOption><FilterOption id="1009547" count="2" label="Sanofi SA"></FilterOption><FilterOption id="27150" count="1" label="Daiichi Sankyo Europe GmbH"></FilterOption></Filter><Filter label="Trial Actions Secondary Interventions Control" name="trialActionsSecondaryInterventionsControl" total="7"><FilterOption id="1545" count="1" label="Anticancer"></FilterOption><FilterOption id="991" count="1" label="Antiviral"></FilterOption><FilterOption id="38206" count="1" label="Biguanide antidiabetic product"></FilterOption><FilterOption id="646" count="1" label="Bronchodilator"></FilterOption><FilterOption id="3189" count="1" label="Corticosteroid agonist"></FilterOption><FilterOption id="399" count="1" label="Hypoglycemic agent"></FilterOption><FilterOption id="2954" count="1" label="Steroidal anti-inflammatory"></FilterOption></Filter><Filter label="Biomarker Type" name="trialBiomarkerTypes" total="5"><FilterOption id="37" count="8" label="Proteomic"></FilterOption><FilterOption id="32" count="7" label="Biochemical"></FilterOption><FilterOption id="38" count="7" label="Genomic"></FilterOption><FilterOption id="31" count="6" label="Physiological"></FilterOption><FilterOption id="39" count="3" label="Anthropomorphic"></FilterOption></Filter><Filter label="Biomarker Role" name="trialBiomarkerRoles" total="2"><FilterOption id="695863716" count="12" label="Therapeutic effect marker"></FilterOption><FilterOption id="1571666123" count="1" label="Disease marker"></FilterOption></Filter><Filter label="Interventions" name="trialInterventions" total="21"><FilterOption id="30712" count="2" label="budesonide + formoterol fumarate, AstraZeneca"></FilterOption><FilterOption id="11603" count="2" label="gefitinib"></FilterOption><FilterOption id="33451" count="2" label="muraglitazar"></FilterOption><FilterOption id="3321" count="1" label="anastrozole"></FilterOption><FilterOption id="2953" count="1" label="docetaxel"></FilterOption><FilterOption id="58762" count="1" label="empagliflozin"></FilterOption><FilterOption id="16026" count="1" label="esomeprazole"></FilterOption><FilterOption id="13572" count="1" label="exenatide"></FilterOption><FilterOption id="46890" count="1" label="glibenclamide"></FilterOption><FilterOption id="45998" count="1" label="interferon alfa-2b"></FilterOption><FilterOption id="4469" count="1" label="irbesartan"></FilterOption><FilterOption id="5665" count="1" label="levetiracetam (oral), UCB"></FilterOption><FilterOption id="54142" count="1" label="NAHE-001"></FilterOption><FilterOption id="46939" count="1" label="olmesartan medoxomil + hydrochlorothiazide (hypertension), Sankyo"></FilterOption><FilterOption id="8946" count="1" label="olmesartan medoxomil"></FilterOption><FilterOption id="29446" count="1" label="piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho"></FilterOption><FilterOption id="3317" count="1" label="quetiapine IR"></FilterOption><FilterOption id="6681" count="1" label="raloxifene"></FilterOption><FilterOption id="4234" count="1" label="risedronate sodium"></FilterOption><FilterOption id="4433" count="1" label="somatropin, Horizon Pharma"></FilterOption><FilterOption id="5265" count="1" label="valproic acid (oral extended-release), Sanofi"></FilterOption></Filter><Filter label="Endpoint Index Primary" name="trialEndpointIndexPrimary" total="66"><FilterOption id="1359" count="4" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Change in HbA1c"></FilterOption><FilterOption id="5986" count="2" label="Asthma - Assessment of Exacerbations - Severity of exacerbation"></FilterOption><FilterOption id="5987" count="2" label="Asthma - Assessment of Exacerbations - Time to first exacerbation"></FilterOption><FilterOption id="22537" count="2" label="End stage renal disease - Glycemic Control Analysis - Assessment of glycosylated hemoglobin (HbA1c)"></FilterOption><FilterOption id="5985" count="1" label="Asthma - Assessment of Exacerbations - Number/rate/frequency/duration of exacerbation"></FilterOption><FilterOption id="9921" count="1" label="Bipolar disorder - Assessment of Bipolar Disorder Symptoms"></FilterOption><FilterOption id="9937" count="1" label="Bipolar disorder - Assessment of Depression Severity by Specific Criteria - Assessment by Montgomery-Asberg Depression Scale (MADRS)"></FilterOption><FilterOption id="10037" count="1" label="Bipolar disorder - Assessment of Disease Relapse/Recurrence - Assessment of time to recurrence"></FilterOption><FilterOption id="9932" count="1" label="Bipolar disorder - Assessment of Manic Symptoms by Specific Scales - Assessment by Young Mania Rating Scale (YMRS)"></FilterOption><FilterOption id="9954" count="1" label="Bipolar disorder - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)"></FilterOption><FilterOption id="9952" count="1" label="Bipolar disorder - Assessment of Psychiatric Symptoms"></FilterOption><FilterOption id="9926" count="1" label="Bipolar disorder - Assessment of Therapy Related Outcomes - Assessment of symptom improvement"></FilterOption><FilterOption id="9315" count="1" label="Breast tumor - Imaging/Radiological Assessments - Assessment by ultrasonography"></FilterOption><FilterOption id="22543" count="1" label="End stage renal disease - Assessment of lipid profiles"></FilterOption><FilterOption id="17119" count="1" label="Epilepsy - Patient Reported Outcomes/Quality of Life Assessments - Assessment of acceptability of therapy"></FilterOption><FilterOption id="7244" count="1" label="Head and neck tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="3809" count="1" label="Hepatitis C virus infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="3808" count="1" label="Hepatitis C virus infection - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="2" count="1" label="Hypertension - Assessment of Blood Pressure (BP) - BP control rate"></FilterOption><FilterOption id="40" count="1" label="Hypertension - Assessment of Diastolic Blood Pressure (DBP) - Seated DBP"></FilterOption><FilterOption id="44" count="1" label="Hypertension - Assessment of Diastolic Blood Pressure (DBP) - Trough DBP"></FilterOption><FilterOption id="31" count="1" label="Hypertension - Assessment of Diastolic Blood Pressure (DBP)"></FilterOption><FilterOption id="170" count="1" label="Hypertension - Assessment of Hemoglobin A1c (HbA1c) Levels"></FilterOption><FilterOption id="220" count="1" label="Hypertension - Assessment of Insulin Sensitivity - Matsuda index/ISI by oral glucose tolerance test (OGTT)"></FilterOption><FilterOption id="292" count="1" label="Hypertension - Assessment of Metabolic Parameters - Diabetes"></FilterOption><FilterOption id="16" count="1" label="Hypertension - Assessment of Systolic Blood Pressure (SBP)"></FilterOption><FilterOption id="223" count="1" label="Hypertension - Assessment of lipid profiles - Assessment of Total Cholesterol"></FilterOption><FilterOption id="225" count="1" label="Hypertension - Assessment of lipid profiles - HDL-C (High-density lipoprotein cholesterol)"></FilterOption><FilterOption id="226" count="1" label="Hypertension - Assessment of lipid profiles - LDL-C (Low-density lipoprotein cholesterol)"></FilterOption><FilterOption id="24859" count="1" label="Hypopituitarism - Assessment of Adipocytes Endocrine Function - Assessment of resistin"></FilterOption><FilterOption id="24898" count="1" label="Hypopituitarism - Assessment of Hormone Levels - Assessment of ghrelin levels"></FilterOption><FilterOption id="24906" count="1" label="Hypopituitarism - Assessment of Hormone Levels - Assessment of leptin"></FilterOption><FilterOption id="24858" count="1" label="Hypopituitarism - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of adiponectin"></FilterOption><FilterOption id="23274" count="1" label="Insulin resistance - Glycemic Control Analysis - Assessment of insulin resistance"></FilterOption><FilterOption id="23071" count="1" label="Lipid metabolism disorder - Anthropometric Assessments - Assessment of anthropometric changes"></FilterOption><FilterOption id="23084" count="1" label="Lipid metabolism disorder - Assessment of Cardiac Function - Assessment of blood pressure"></FilterOption><FilterOption id="23050" count="1" label="Lipid metabolism disorder - Assessment of High Density Lipoprotein (HDL)"></FilterOption><FilterOption id="23051" count="1" label="Lipid metabolism disorder - Assessment of Low-Density Lipoprotein (LDL)"></FilterOption><FilterOption id="23049" count="1" label="Lipid metabolism disorder - Assessment of lipid profiles - Assessment of Total Cholesterol"></FilterOption><FilterOption id="23053" count="1" label="Lipid metabolism disorder - Assessment of lipid profiles"></FilterOption><FilterOption id="23114" count="1" label="Lipid metabolism disorder - Glycemic Control Analysis - Assessment of HbA1c"></FilterOption><FilterOption id="8608" count="1" label="Lung tumor - Assessment of Oncogenes/Oncoproteins - Assessment of EGFR mutation/ amplification status"></FilterOption><FilterOption id="23556" count="1" label="Menopause - Assessment of Biomarkers - Assessment of bone markers"></FilterOption><FilterOption id="23553" count="1" label="Menopause - Assessment of Bone - Assessment by Bone mineral density (BMD)"></FilterOption><FilterOption id="23531" count="1" label="Menopause - Assessment of Endometrium"></FilterOption><FilterOption id="20952" count="1" label="Metabolic syndrome X - Glycemic Control Analysis - Assessment of insulin resistance"></FilterOption><FilterOption id="1504" count="1" label="Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of abdominal circumference"></FilterOption><FilterOption id="1580" count="1" label="Non-insulin dependent diabetes - Assessment of Blood Pressure (BP)"></FilterOption><FilterOption id="1547" count="1" label="Non-insulin dependent diabetes - Assessment of Cardiovascular Events - Hypertension"></FilterOption><FilterOption id="2430" count="1" label="Non-insulin dependent diabetes - Assessment of Diabetic Events/Risk Factors - Incidence/onset of diabetes"></FilterOption><FilterOption id="1358" count="1" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels"></FilterOption><FilterOption id="1452" count="1" label="Non-insulin dependent diabetes - Assessment of lipid profiles - Assessment of Total Cholesterol"></FilterOption><FilterOption id="1454" count="1" label="Non-insulin dependent diabetes - Assessment of lipid profiles - HDL-C (High-density lipoprotein cholesterol)"></FilterOption><FilterOption id="1455" count="1" label="Non-insulin dependent diabetes - Assessment of lipid profiles - LDL-C (Low-density lipoprotein cholesterol)"></FilterOption><FilterOption id="1483" count="1" label="Non-insulin dependent diabetes - Assessment of lipid profiles - Non-HDL levels"></FilterOption><FilterOption id="1505" count="1" label="Non-insulin dependent diabetes - Obesity, Body Weight &amp; Fat Tissue Assessment - Hip circumference"></FilterOption><FilterOption id="20404" count="1" label="Obesity - Anthropometric Assessments - Assessment of waist-hip circumference"></FilterOption><FilterOption id="20554" count="1" label="Obesity - Assessment of Cardiac Function - Assessment of blood pressure"></FilterOption><FilterOption id="20406" count="1" label="Obesity - Assessment of HbA1c levels"></FilterOption><FilterOption id="20455" count="1" label="Obesity - Assessment of lipid profiles - Assessment of LDL-C"></FilterOption><FilterOption id="20458" count="1" label="Obesity - Assessment of lipid profiles - Assessment of cholesterol"></FilterOption><FilterOption id="13771" count="1" label="Osteoporosis - Assessment of Bone - Assessment by Bone mineral density (BMD)"></FilterOption><FilterOption id="13772" count="1" label="Osteoporosis - Assessment of Bone"></FilterOption><FilterOption id="13844" count="1" label="Osteoporosis - Assessment of Therapy Related Outcomes - Assessment of efficacy"></FilterOption><FilterOption id="7191" count="1" label="Prostate tumor - Assessment of Safety and Tolerability - Assessment of treatment emergent adverse events"></FilterOption><FilterOption id="14161" count="1" label="Urinary tract infection - Assessment of Clinical Response"></FilterOption></Filter><Filter label="Sponsors/Collaborators" name="trialCompanies" total="13"><FilterOption id="14190" count="12" label="AstraZeneca plc"></FilterOption><FilterOption id="15065" count="3" label="Bristol-Myers Squibb Co"></FilterOption><FilterOption id="17810" count="3" label="Eli Lilly &amp; Co"></FilterOption><FilterOption id="1009547" count="2" label="Sanofi SA"></FilterOption><FilterOption id="22586" count="1" label="Boehringer Ingelheim Corp"></FilterOption><FilterOption id="27150" count="1" label="Daiichi Sankyo Europe GmbH"></FilterOption><FilterOption id="1020322" count="1" label="Daiichi Sankyo Inc"></FilterOption><FilterOption id="1016499" count="1" label="Digna Biotech SL"></FilterOption><FilterOption id="29708" count="1" label="Ferring Pharmaceuticals SA"></FilterOption><FilterOption id="22186" count="1" label="Solvay Pharmaceuticals Inc"></FilterOption><FilterOption id="22784" count="1" label="UCB Pharma Inc"></FilterOption><FilterOption id="27724" count="1" label="Warner Chilcott plc"></FilterOption><FilterOption id="14112" count="1" label="Wyeth"></FilterOption></Filter><Filter label="Last Changed Date By Day" name="trialDateChangeLastByDay" total="22"><FilterOption count="2" label="2013-09-14"></FilterOption><FilterOption count="2" label="2013-12-02"></FilterOption><FilterOption count="1" label="2012-09-05"></FilterOption><FilterOption count="1" label="2014-01-28"></FilterOption><FilterOption count="1" label="2014-03-18"></FilterOption><FilterOption count="1" label="2014-04-07"></FilterOption><FilterOption count="1" label="2014-05-28"></FilterOption><FilterOption count="1" label="2015-02-24"></FilterOption><FilterOption count="1" label="2015-11-30"></FilterOption><FilterOption count="1" label="2016-11-26"></FilterOption><FilterOption count="1" label="2017-01-27"></FilterOption><FilterOption count="1" label="2017-04-01"></FilterOption><FilterOption count="1" label="2018-05-02"></FilterOption><FilterOption count="1" label="2018-05-12"></FilterOption><FilterOption count="1" label="2018-06-18"></FilterOption><FilterOption count="1" label="2018-06-30"></FilterOption><FilterOption count="1" label="2018-08-27"></FilterOption><FilterOption count="1" label="2018-11-14"></FilterOption><FilterOption count="1" label="2018-11-17"></FilterOption><FilterOption count="1" label="2018-11-29"></FilterOption><FilterOption count="1" label="2018-12-04"></FilterOption><FilterOption count="1" label="2019-01-26"></FilterOption></Filter><Filter label="Trial Date End By Month" name="trialDateEndByMonth" total="22"><FilterOption count="2" label="200606"></FilterOption><FilterOption count="1" label="200309"></FilterOption><FilterOption count="1" label="200508"></FilterOption><FilterOption count="1" label="200509"></FilterOption><FilterOption count="1" label="200511"></FilterOption><FilterOption count="1" label="200603"></FilterOption><FilterOption count="1" label="200605"></FilterOption><FilterOption count="1" label="200607"></FilterOption><FilterOption count="1" label="200610"></FilterOption><FilterOption count="1" label="200702"></FilterOption><FilterOption count="1" label="200707"></FilterOption><FilterOption count="1" label="200709"></FilterOption><FilterOption count="1" label="200803"></FilterOption><FilterOption count="1" label="200804"></FilterOption><FilterOption count="1" label="200805"></FilterOption><FilterOption count="1" label="200812"></FilterOption><FilterOption count="1" label="200907"></FilterOption><FilterOption count="1" label="200910"></FilterOption><FilterOption count="1" label="201102"></FilterOption><FilterOption count="1" label="201207"></FilterOption><FilterOption count="1" label="201212"></FilterOption><FilterOption count="1" label="201301"></FilterOption></Filter><Filter label="Trial Date Start By Month" name="trialDateStartByMonth" total="20"><FilterOption count="2" label="200307"></FilterOption><FilterOption count="2" label="200405"></FilterOption><FilterOption count="2" label="200406"></FilterOption><FilterOption count="2" label="200505"></FilterOption><FilterOption count="1" label="200203"></FilterOption><FilterOption count="1" label="200205"></FilterOption><FilterOption count="1" label="200304"></FilterOption><FilterOption count="1" label="200311"></FilterOption><FilterOption count="1" label="200404"></FilterOption><FilterOption count="1" label="200510"></FilterOption><FilterOption count="1" label="200511"></FilterOption><FilterOption count="1" label="200604"></FilterOption><FilterOption count="1" label="200702"></FilterOption><FilterOption count="1" label="200703"></FilterOption><FilterOption count="1" label="200903"></FilterOption><FilterOption count="1" label="200905"></FilterOption><FilterOption count="1" label="201003"></FilterOption><FilterOption count="1" label="201005"></FilterOption><FilterOption count="1" label="201007"></FilterOption><FilterOption count="1" label="201103"></FilterOption></Filter><Filter label="Trial Phase" name="trialPhase" total="8"><FilterOption id="C3" count="7" label="Phase 3 Clinical"></FilterOption><FilterOption id="C4" count="6" label="Phase 4 Clinical"></FilterOption><FilterOption id="NS" count="5" label="Phase not specified"></FilterOption><FilterOption id="C3B" count="2" label="Phase 3b Clinical"></FilterOption><FilterOption id="C12" count="1" label="Phase 1/Phase 2 Clinical"></FilterOption><FilterOption id="C2" count="1" label="Phase 2 Clinical"></FilterOption><FilterOption id="C23" count="1" label="Phase 2/Phase 3 Clinical"></FilterOption><FilterOption id="PNA" count="1" label="Phase Not Applicable"></FilterOption></Filter><Filter label="Inclusion Criteria Index" name="trialInclusionCriteriaIndex" total="100"><FilterOption id="901" count="4" label="Non-insulin dependent diabetes - Subjects with specific level of glycemic control - Subjects with Moderate Glycemic Control"></FilterOption><FilterOption id="610" count="3" label="Non-insulin dependent diabetes - Obese Subjects - Obese subjects (Grade 2 obesity, BMI= 30 to 39.9)"></FilterOption><FilterOption id="609" count="3" label="Non-insulin dependent diabetes - Obese Subjects - Overweight subjects (Grade 1 obesity, BMI= 25 to 29.9)"></FilterOption><FilterOption id="584" count="3" label="Non-insulin dependent diabetes - Subjects with Diabetes Mellitus - Subjects with type 2 diabetes mellitus"></FilterOption><FilterOption id="606" count="3" label="Non-insulin dependent diabetes - Subjects with specific level of glycemic control - Subjects with Good Glycemic Control"></FilterOption><FilterOption id="607" count="3" label="Non-insulin dependent diabetes - Subjects with specific level of glycemic control - Subjects with Poor/Inadequate Glycemic Control"></FilterOption><FilterOption id="4322" count="2" label="Asthma - Subjects with Diagnosis of Asthma"></FilterOption><FilterOption id="22368" count="2" label="Asthma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for asthma drugs"></FilterOption><FilterOption id="22364" count="2" label="Asthma - Subjects with Persistent Asthma - Subjects with mild persistent asthma"></FilterOption><FilterOption id="22365" count="2" label="Asthma - Subjects with Persistent Asthma - Subjects with moderate persistent asthma"></FilterOption><FilterOption id="22366" count="2" label="Asthma - Subjects with Persistent Asthma - Subjects with severe persistent asthma"></FilterOption><FilterOption id="4441" count="2" label="Head and neck tumor - Subjects with Progressive/Treatment Refractory Disease"></FilterOption><FilterOption id="4794" count="2" label="Head and neck tumor - Subjects with Specific Histological Sub-type of Head and Neck Cancer - Subjects with squamous cell head and neck carcinoma"></FilterOption><FilterOption id="20758" count="2" label="Menopause - Subjects with Protocol Specified Menstrual Status - Postmenopausal subjects"></FilterOption><FilterOption id="612" count="2" label="Non-insulin dependent diabetes - Obese Subjects - Subjects with morbid obesity (Grade 3 obesity, BMI=40)"></FilterOption><FilterOption id="8685" count="2" label="Osteoporosis - Subjects with Postmenopausal Osteoporosis"></FilterOption><FilterOption id="8682" count="2" label="Osteoporosis - Subjects with Primary Osteoporosis"></FilterOption><FilterOption id="2710" count="1" label="Asthma - Subjects with Exacerbations/Acute Asthma"></FilterOption><FilterOption id="5796" count="1" label="Bipolar disorder - Subjects Fulfilling Protocol Specific Diagnostic Criteria - Diagnosed by Diagnostic and Statistical Manual (DSM IV) criteria"></FilterOption><FilterOption id="5788" count="1" label="Bipolar disorder - Subjects with Bipolar Disorder - Subjects with bipolar I disorder"></FilterOption><FilterOption id="5803" count="1" label="Bipolar disorder - Subjects with Symptomatic Disease - Subjects with depression"></FilterOption><FilterOption id="5806" count="1" label="Bipolar disorder - Subjects with Symptomatic Disease - Subjects with depression and mania"></FilterOption><FilterOption id="5805" count="1" label="Bipolar disorder - Subjects with Symptomatic Disease - Subjects with mania"></FilterOption><FilterOption id="5808" count="1" label="Bipolar disorder - Subjects with Symptomatic Disease - Subjects with psychosis"></FilterOption><FilterOption id="5809" count="1" label="Bipolar disorder - Subjects with Symptomatic Disease - Subjects without psychotic features"></FilterOption><FilterOption id="4817" count="1" label="Breast tumor - Postmenopausal Breast Cancer Women"></FilterOption><FilterOption id="22394" count="1" label="Breast tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer biological therapy"></FilterOption><FilterOption id="4894" count="1" label="Breast tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer chemotherapy"></FilterOption><FilterOption id="4895" count="1" label="Breast tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer hormonal therapy"></FilterOption><FilterOption id="4904" count="1" label="Breast tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer radiotherapy"></FilterOption><FilterOption id="4808" count="1" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer"></FilterOption><FilterOption id="4809" count="1" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Progesterone receptor positive (PR+) breast cancer"></FilterOption><FilterOption id="22398" count="1" label="Breast tumor - Subjects with Resectable Tumor"></FilterOption><FilterOption id="17667" count="1" label="End stage renal disease - Subjects co-morbid with renal disease/disorder - Subjects with other cardiac disease/associated nephropathy"></FilterOption><FilterOption id="17664" count="1" label="End stage renal disease - Subjects with Diabetes/Diabetic Nephropathy"></FilterOption><FilterOption id="17652" count="1" label="End stage renal disease - Subjects with Dialysis Dependant Chronic Kidney Disease(DD-CKD) - Subjects with stage 5 CKD/end stage renal disease(ESRD)"></FilterOption><FilterOption id="17691" count="1" label="End stage renal disease - Subjects with History of/Scheduled to Receive Therapy - Subjects on antidiabetics"></FilterOption><FilterOption id="17697" count="1" label="End stage renal disease - Subjects with History of/Scheduled to Receive Therapy - Subjects on nutritional supplements/dietary therapy"></FilterOption><FilterOption id="17638" count="1" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 2 chronic kidney disease"></FilterOption><FilterOption id="17642" count="1" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 3 chronic kidney disease"></FilterOption><FilterOption id="17644" count="1" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 4 chronic kidney disease"></FilterOption><FilterOption id="15257" count="1" label="Epilepsy - Subjects with Diagnosis of Epilepsy - Subjects with partial onset epilepsy"></FilterOption><FilterOption id="15273" count="1" label="Epilepsy - Subjects with Epilepsy based on Seizure Type - Subjects with complex partial seizures"></FilterOption><FilterOption id="15274" count="1" label="Epilepsy - Subjects with Epilepsy based on Seizure Type - Subjects with partial seizures with secondary generalization"></FilterOption><FilterOption id="15272" count="1" label="Epilepsy - Subjects with Epilepsy based on Seizure Type - Subjects with simple partial seizures"></FilterOption><FilterOption id="15326" count="1" label="Epilepsy - Subjects with History of/Scheduled to Receive Therapy - Subjects with history/ scheduled to receive pyrrolidine derivatives"></FilterOption><FilterOption id="7086" count="1" label="Head and neck tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="4365" count="1" label="Head and neck tumor - Subjects with Laryngeal Cancer - Subjects with glottic laryngeal cancer"></FilterOption><FilterOption id="4366" count="1" label="Head and neck tumor - Subjects with Laryngeal Cancer - Subjects with subglottic laryngeal cancer"></FilterOption><FilterOption id="4364" count="1" label="Head and neck tumor - Subjects with Laryngeal Cancer - Subjects with supraglottic laryngeal cancer"></FilterOption><FilterOption id="4371" count="1" label="Head and neck tumor - Subjects with Measurable Disease - Subjects with measurable disease as per RECIST criteria"></FilterOption><FilterOption id="4359" count="1" label="Head and neck tumor - Subjects with Oral Cancer"></FilterOption><FilterOption id="4363" count="1" label="Head and neck tumor - Subjects with Pharyngeal Cancer - Subjects with hypopharyngeal cancer"></FilterOption><FilterOption id="4362" count="1" label="Head and neck tumor - Subjects with Pharyngeal Cancer - Subjects with oropharyngeal cancer"></FilterOption><FilterOption id="4442" count="1" label="Head and neck tumor - Subjects with Progressive/Treatment Refractory Disease - Subjects with progressive/refractory HNC to chemotherapy"></FilterOption><FilterOption id="4397" count="1" label="Head and neck tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="4398" count="1" label="Head and neck tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="4451" count="1" label="Head and neck tumor - Subjects with Relapsed/Recurrent Disease"></FilterOption><FilterOption id="4389" count="1" label="Head and neck tumor - Subjects with TNM Stage IV Head and Neck Cancer - Subjects with TNM stage IV C HNC"></FilterOption><FilterOption id="6663" count="1" label="Hepatitis C virus infection - Subjects Infected with HCV Genotype 1"></FilterOption><FilterOption id="1788" count="1" label="Hepatitis C virus infection - Subjects with Abnormal Liver Function Tests - Subjects with abnormal alanine transaminase (ALT) levels"></FilterOption><FilterOption id="1789" count="1" label="Hepatitis C virus infection - Subjects with Abnormal Liver Function Tests - Subjects with abnormal aspartate transaminase (AST) levels"></FilterOption><FilterOption id="1751" count="1" label="Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection"></FilterOption><FilterOption id="1792" count="1" label="Hepatitis C virus infection - Subjects with Non-invasive Evidence of Liver Fibrosis - Subjects with liver fibroscan findings"></FilterOption><FilterOption id="1786" count="1" label="Hepatitis C virus infection - Subjects with Normal Liver Function Tests/Liver Biopsy"></FilterOption><FilterOption id="1764" count="1" label="Hepatitis C virus infection - Subjects with Positive Serological Markers for Hepatitis C - Subjects positive for HCV RNA"></FilterOption><FilterOption id="1763" count="1" label="Hepatitis C virus infection - Subjects with Positive Serological Markers for Hepatitis C - Subjects positive for anti-HCV antibody"></FilterOption><FilterOption id="1841" count="1" label="Hepatitis C virus infection - Subjects with Prior Hepatitis C Therapy"></FilterOption><FilterOption id="1844" count="1" label="Hepatitis C virus infection - Subjects with Treatment Resistant Disease - Treatment failure subjects"></FilterOption><FilterOption id="1842" count="1" label="Hepatitis C virus infection - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="110" count="1" label="Hypertension - Obese Subjects"></FilterOption><FilterOption id="50" count="1" label="Hypertension - Subjects with Diabetic Complications"></FilterOption><FilterOption id="58" count="1" label="Hypertension - Subjects with Dyslipidemia"></FilterOption><FilterOption id="80" count="1" label="Hypertension - Subjects with History of/Scheduled to Receive Therapy - Subjects on monotherapy"></FilterOption><FilterOption id="79" count="1" label="Hypertension - Subjects with History of/Scheduled to Receive Therapy"></FilterOption><FilterOption id="6" count="1" label="Hypertension - Subjects with Primary/Essential Hypertension - Subjects with moderate/stage 2 (JNC 6) hypertension"></FilterOption><FilterOption id="220" count="1" label="Hypertension - Subjects with Primary/Essential Hypertension - Subjects with severe/stage 3 (JNC 6) hypertension"></FilterOption><FilterOption id="1" count="1" label="Hypertension - Subjects with Primary/Essential Hypertension"></FilterOption><FilterOption id="21" count="1" label="Hypertension - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="78" count="1" label="Hypertension - Treatment Naive Subjects"></FilterOption><FilterOption id="21484" count="1" label="Hypopituitarism - Subjects with Hypopituitarism - Subjects with growth hormone deficiency"></FilterOption><FilterOption id="21492" count="1" label="Hypopituitarism - Subjects with Protocol Specified Tanner Stage - Subjects with tanner stage &gt;=1"></FilterOption><FilterOption id="20228" count="1" label="Insulin resistance - Subjects with Acceptable Glycemic Levels - Acceptable fasting glucose"></FilterOption><FilterOption id="20233" count="1" label="Insulin resistance - Subjects with Acceptable Lipid Profile - Acceptable HDL levels"></FilterOption><FilterOption id="20232" count="1" label="Insulin resistance - Subjects with Acceptable Lipid Profile - Acceptable triglycerides"></FilterOption><FilterOption id="20237" count="1" label="Insulin resistance - Subjects with Normal/Acceptable Laboratory Criteria - Abnormal blood pressure"></FilterOption><FilterOption id="20031" count="1" label="Lipid metabolism disorder - Subjects with Risk Factors for Coronary Heart Disease (CHD)"></FilterOption><FilterOption id="3957" count="1" label="Lung tumor - Subjects Confirmed of Lung Cancer by Specific Modes - Subjects with cytologically/histologically confirmed diagnosis of lung cancer"></FilterOption><FilterOption id="3940" count="1" label="Lung tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="3900" count="1" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"></FilterOption><FilterOption id="4074" count="1" label="Lung tumor - Subjects with Protocol Specified Compliance Status - Subjects able to comply with the study protocol procedures/ requirements"></FilterOption><FilterOption id="3938" count="1" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with advanced stage lung cancer"></FilterOption><FilterOption id="3935" count="1" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage IIIB lung cancer"></FilterOption><FilterOption id="3936" count="1" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage IV lung cancer"></FilterOption><FilterOption id="20767" count="1" label="Menopause - Subjects with Cancer"></FilterOption><FilterOption id="20760" count="1" label="Menopause - Subjects with Premature Menopause - Subjects with surgical menopause"></FilterOption><FilterOption id="20773" count="1" label="Menopause - Subjects with Protocol Specified Bone Mineral Density(BMD)"></FilterOption><FilterOption id="20777" count="1" label="Menopause - Subjects with history/Scheduled for Chemotherapy Therapy"></FilterOption><FilterOption id="20776" count="1" label="Menopause - Subjects with history/Scheduled for Hormonal Therapy"></FilterOption><FilterOption id="20770" count="1" label="Menopause - Subjects with protocol Specified Hormonal Levels - Subjects with protocol specified FSH levels"></FilterOption></Filter><Filter label="Trial Interventions Control Alone Name Display" name="trialInterventionsControlAloneNameDisplay" total="2"><FilterOption id="6050" count="1" label="metformin hydrochloride"></FilterOption><FilterOption id="54142" count="1" label="NAHE-001"></FilterOption></Filter><Filter label="Trial Actions Primary Interventions Control" name="trialActionsPrimaryInterventionsControl" total="3"><FilterOption id="8805" count="1" label="AMP activated protein kinase stimulator"></FilterOption><FilterOption id="40" count="1" label="Beta 2 adrenoceptor agonist"></FilterOption><FilterOption id="51174" count="1" label="Interferon alpha 5 ligand"></FilterOption></Filter><Filter label="Trial Indications Adverse" name="trialIndicationsAdverse" total="31"><FilterOption id="102" count="5" label="Diarrhea"></FilterOption><FilterOption id="226" count="4" label="Nausea"></FilterOption><FilterOption id="404" count="2" label="Constipation"></FilterOption><FilterOption id="402" count="2" label="Edema"></FilterOption><FilterOption id="110" count="2" label="Emesis"></FilterOption><FilterOption id="148" count="2" label="Headache"></FilterOption><FilterOption id="445" count="2" label="Hypoglycemia"></FilterOption><FilterOption id="191" count="2" label="Influenza virus infection"></FilterOption><FilterOption id="2274" count="2" label="Rhinopharyngitis"></FilterOption><FilterOption id="1009" count="2" label="Urinary tract infection"></FilterOption><FilterOption id="2954" count="2" label="Weight gain"></FilterOption><FilterOption id="13" count="1" label="Alopecia"></FilterOption><FilterOption id="17" count="1" label="Anemia"></FilterOption><FilterOption id="3038" count="1" label="Appetite loss"></FilterOption><FilterOption id="2439" count="1" label="Arthralgia"></FilterOption><FilterOption id="3221" count="1" label="Back pain"></FilterOption><FilterOption id="1091" count="1" label="Bone injury"></FilterOption><FilterOption id="50" count="1" label="Bronchitis"></FilterOption><FilterOption id="1559" count="1" label="Congestive heart failure"></FilterOption><FilterOption id="3454" count="1" label="Dizziness"></FilterOption><FilterOption id="432" count="1" label="Dyspepsia"></FilterOption><FilterOption id="2085" count="1" label="Dysphagia"></FilterOption><FilterOption id="501" count="1" label="Extrapyramidal syndrome"></FilterOption><FilterOption id="1833" count="1" label="Fever"></FilterOption><FilterOption id="680" count="1" label="Leukopenia"></FilterOption><FilterOption id="1991" count="1" label="Neutropenia"></FilterOption><FilterOption id="20" count="1" label="Pain"></FilterOption><FilterOption id="3020" count="1" label="Skin rash"></FilterOption><FilterOption id="1016" count="1" label="Stomatitis"></FilterOption><FilterOption id="516" count="1" label="Upper respiratory tract infection"></FilterOption><FilterOption id="2955" count="1" label="Weight loss"></FilterOption></Filter></Filters><SearchResults><Trial Id="93718"><Indications><Indication>Constipation</Indication></Indications><CompaniesSponsor><Company>Solvay Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2006-06-30T00:00:00Z</DateEnd><DateStart>2002-03-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT00160290</Identifier><Identifier>S105.4.106</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Plantago ovata alone</Intervention><Intervention>lactulose alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>97</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><Teaser>The purpose of this study was to demonstrate that lactulose acts as a stool softener, relieving the pain at defecation, improving the number of defecations and regulating the colonic transit time in patients suffering of hemorrhoids or anal fissure; to compare efficacy and quality of life in patients treated either with lactulose or plantago ovata.</Teaser><TrialCategories><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Trial to Evaluate Effect of Lactulose on Hard Stools in Patients With Hemorrhoids or Anal Fissures</TitleDisplay><PrimaryCompletionDate type="Actual">2006-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>51 Months</TrialDuration><NumberOfSites>8</NumberOfSites><ContactNames><Name>Global Clinical Director Solvay</Name></ContactNames></Trial><Trial Id="77335"><Indications><Indication>Growth hormone deficiency</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Growth hormone ligand</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cloning technology</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Ferring Pharmaceuticals SA</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-01-27T00:00:00Z</DateChangeLast><DateEnd>2008-03-31T00:00:00Z</DateEnd><DateStart>2005-05-31T00:00:00Z</DateStart><Identifiers><Identifier>FAYDS</Identifier><Identifier>FER-SOM-2004-01</Identifier><Identifier>NCT01351818</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>somatropin, Horizon Pharma alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>62</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to assess the influence of exogenous GH (growth hormone) ( somatropin ) administration on adipocyte endocrine function (leptin, adiponectin, and resistin) and on ghrelin secretion in children with delayed growth due to GH deficiency. The hypothesis of this study was that the hormones produced by the adipocyte (leptin, adiponectin, and resistin) and ghrelin may exert a certain control on production of GH and insulin-like growth factor-1 (IGF-1), and GH may in turn</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Hypopituitarism - Anthropometric Assessments - Assessment of BMI</EndpointIndex><EndpointIndex>Hypopituitarism - Anthropometric Assessments - Assessment of height</EndpointIndex><EndpointIndex>Hypopituitarism - Anthropometric Assessments - Assessment of weight</EndpointIndex><EndpointIndex>Hypopituitarism - Assessment of Adipocytes Endocrine Function - Assessment of resistin</EndpointIndex><EndpointIndex>Hypopituitarism - Assessment of Hormone Levels - Assessment of ghrelin levels</EndpointIndex><EndpointIndex>Hypopituitarism - Assessment of Hormone Levels - Assessment of leptin</EndpointIndex><EndpointIndex>Hypopituitarism - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of adiponectin</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>FAYDS: Adipocyte Function and Somatropin Deficiency</TitleDisplay><PatientSegmentTerms><PatientSegment>Hypopituitarism - Subjects with Growth hormone (GH) Deficiency</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Adiponectin </BiomarkerName><BiomarkerName> Appetite regulating hormone </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> Body height </BiomarkerName><BiomarkerName> Insulin-like growth factor 1 </BiomarkerName><BiomarkerName> Leptin </BiomarkerName><BiomarkerName> Resistin </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>34 Months</TrialDuration><NumberOfSites>12</NumberOfSites><ContactNames><Name>Clinical Development Support</Name></ContactNames></Trial><Trial Id="68274"><Indications><Indication>Non-insulin dependent diabetes</Indication><Indication>Renal insufficiency</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium glucose transporter-2 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Eli Lilly &amp; Co</Company></CompaniesCollaborator><CompaniesSponsor><Company>Boehringer Ingelheim Corp</Company></CompaniesSponsor><Countries><Country>Poland</Country><Country>Malaysia</Country><Country>Philippines</Country><Country>Hong Kong</Country><Country>France</Country><Country>Canada</Country><Country>Netherlands</Country><Country>Spain</Country><Country>Slovakia</Country><Country>India</Country><Country>Portugal</Country><Country>US</Country><Country>Russian Federation</Country><Country>UK</Country><Country>South Africa</Country></Countries><DateChangeLast>2018-11-14T00:00:00Z</DateChangeLast><DateEnd>2012-07-31T00:00:00Z</DateEnd><DateStart>2010-07-31T00:00:00Z</DateStart><Identifiers><Identifier>1245.36</Identifier><Identifier>2009-016179-31</Identifier><Identifier>EMPA-REG RENAL</Identifier><Identifier>NCT01164501</Identifier><Identifier>NMRR-10-719-6095</Identifier></Identifiers><IndicationsAdverse><Indication>Bone injury</Indication><Indication>Hypoglycemia</Indication><Indication>Urinary tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>empagliflozin (mild RI) alone</Intervention><Intervention>empagliflozin (moderate RI) alone</Intervention><Intervention>empagliflozin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>741</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study was designed to evaluate the efficacy and safety of the BI-10773 in type 2 diabetic patients with renal impairment (RI) in order to provide these data for approval for BI-10773 as an antidiabetic agent by regulatory authorities. By 2012, the study was completed in 741 patients [ 1354812 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>End stage renal disease - Glycemic Control Analysis - Assessment of glycosylated hemoglobin (HbA1c)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of abdominal circumference</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of body weight</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Change in HbA1c</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Time to HbA1c response [Time to HbA1c target]</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>EMPA-REG RENAL: Efficacy and Safety of Empagliflozin (BI-10773) in Patients With Type 2 Diabetes and Renal Impairment</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Subjects by disease severity - Subjects with stage 5 chronic kidney disease/end stage renal disease(ESRD)</PatientSegment><PatientSegment>End stage renal disease - Subjects with Diabetes/Diabetic Nephropathy</PatientSegment><PatientSegment>End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 2 chronic kidney disease</PatientSegment><PatientSegment>End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 3 chronic kidney disease</PatientSegment><PatientSegment>End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 4 chronic kidney disease</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects on Treatment/Requiring &gt;1 Antidiabetic Agent</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Good Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Poor/Inadequate Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with comorbid conditions - Subjects with obesity</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>113</NumberOfSites><ContactNames><Name>Azmira Khalid</Name><Name>Boehringer Ingelheim</Name><Name>Samantha Hew</Name><Name>Zaiton Saliman</Name></ContactNames></Trial><Trial Id="66332"><Indications><Indication>Hepatitis C virus infection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Interferon alpha 5 ligand</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Interferon alpha 5 ligand</Action><Action>Interferon alpha ligand modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Antiviral</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiviral</Action><Action>Systemic dermatological antiviral product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Infusion</Technology><Technology>Intramuscular formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Peptide</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Digna Biotech SL</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2013-12-02T00:00:00Z</DateChangeLast><DateEnd>2013-01-31T00:00:00Z</DateEnd><DateStart>2010-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2009-012924-10</Identifier><Identifier>NAHE001-CHC-01</Identifier><Identifier>NCT01121731</Identifier></Identifiers><InterventionsControlDisplay><Intervention>NAHE-001 alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>interferon alfa-2b alone</Intervention><Intervention>NAHE-001 plus interferon alfa-2b</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>70</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this study is to determine if 3 MIU of interferon-alpha 5 in monotherapy, and 1.5 MIU of interferon-alpha 5 combined with 1.5 MIU of interferon-alpha 2b (Intron A), are safe dose levels as well as to investigate the antiviral efficacy and pharmacodynamics (PD) of such doses and drugs in treatment-experienced HCV patients with genotype 1 chronic infection, after 29 days of treatment. The study is also intended to determine pharmacokinetics (PK) of the safe dose achieved of interferon-alpha</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Phase I/II Clinical Trial With Interferon Alpha 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatitis C virus infection - Subjects Infected with HCV Genotype 1</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Prior Hepatitis C Therapy</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>32 Months</TrialDuration><NumberOfSites>8</NumberOfSites><ContactNames><Name>Jesús Prieto</Name></ContactNames></Trial><Trial Id="5912"><Indications><Indication>Essential hypertension</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Angiotensin II AT-1 receptor antagonist</Action><Action>Angiotensin II receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action><Action>Diuretic agent</Action><Action>Vasodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Daiichi Sankyo Europe GmbH</Company></CompaniesCollaborator><CompaniesSponsor><Company>Daiichi Sankyo Inc</Company></CompaniesSponsor><Countries><Country>Spain</Country><Country>Ukraine</Country><Country>Germany</Country><Country>France</Country><Country>Czech Republic</Country><Country>Poland</Country><Country>Bulgaria</Country></Countries><DateChangeLast>2018-08-27T00:00:00Z</DateChangeLast><DateEnd>2008-05-31T00:00:00Z</DateEnd><DateStart>2007-02-28T00:00:00Z</DateStart><Identifiers><Identifier>CS866CM-B-E301</Identifier><Identifier>NCT00430508</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>olmesartan medoxomil + hydrochlorothiazide (hypertension), Sankyo alone</Intervention><Intervention>olmesartan medoxomil alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>972</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study aimed to evaluate the effect of two different dosages of the combination of olmesartan + hydrochlorothiazide on blood pressure reduction in patients with moderate or severe high blood pressure.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - 24-hour mean ADBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Day-time mean ADBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Night-time mean ADBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Blood Pressure (BP) - BP control rate</EndpointIndex><EndpointIndex>Hypertension - Assessment of Diastolic Blood Pressure (DBP) - Seated DBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Diastolic Blood Pressure (DBP) - Trough DBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Systolic Blood Pressure (SBP) - Seated SBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Systolic Blood Pressure (SBP) - Trough SBP</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>European Ancestry</Term></TermsPatientSelection><TitleDisplay>Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension</TitleDisplay><PatientSegmentTerms><PatientSegment>Hypertension - Subjects with Primary/Essential Hypertension</PatientSegment><PatientSegment>Hypertension - Subjects with Primary/Essential Hypertension - Subjects with stage 2 (JNC 6) hypertension</PatientSegment><PatientSegment>Hypertension - Subjects with Primary/Essential Hypertension - Subjects with stage 3 (JNC 6) hypertension</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Diastolic blood pressure </BiomarkerName><BiomarkerName> Systolic blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>54</NumberOfSites><ContactNames><Name>Professor Lars Christian Rump, M.D.</Name></ContactNames></Trial><Trial Id="43050"><Indications><Indication>Metastatic head and neck cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>EGFR family tyrosine kinase receptor inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Cell cycle inhibitor</Action><Action>Microtubule inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Natural product</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>AstraZeneca plc</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-04-01T00:00:00Z</DateChangeLast><DateEnd>2006-03-31T00:00:00Z</DateEnd><DateStart>2003-07-31T00:00:00Z</DateStart><Identifiers><Identifier>1839IL/0504</Identifier><Identifier>NCT00242762</Identifier></Identifiers><IndicationsAdverse><Indication>Alopecia</Indication><Indication>Anemia</Indication><Indication>Appetite loss</Indication><Indication>Diarrhea</Indication><Indication>Dysphagia</Indication><Indication>Emesis</Indication><Indication>Fever</Indication><Indication>Leukopenia</Indication><Indication>Nausea</Indication><Indication>Neutropenia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Variable regimens including ZD-1839 + docetaxel + cisplatin , cisplatin , docetaxel , gefitinib</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>36</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of the study was to evaluate the activity of the combination ZD-1839 , docetaxel and cisplatin in subjects with recurrent and/or metastatic head and neck cancer by estimating the objective response rate (complete response [CR] and partial response [PR]) at study closure.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Safety and Tolerability - Assessment of chemotherapy induced nausea and vomiting</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Survival - Assessment of median survival</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Head and neck tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>ZD-1839 (Iressa) in Combination With Docetaxel And Cisplatin in Subjects With Metastatic Head And Neck Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Head and neck tumor - Subjects with Advanced/Metastatic Head and Neck Cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Laryngeal Cancer - Subjects with glottic laryngeal cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Laryngeal Cancer - Subjects with subglottic laryngeal cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Laryngeal Cancer - Subjects with supraglottic laryngeal cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Oral Cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Pharyngeal Cancer - Subjects with hypopharyngeal cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Pharyngeal Cancer - Subjects with oropharyngeal cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Relapsed/Recurrent Head and Neck Cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Specific Histological Sub-type of HNC - Subjects with squamous cell carcinoma</PatientSegment><PatientSegment>Head and neck tumor - Subjects with TNM Stage IV Head and Neck Cancer - Subjects with TNM stage IVc HNC</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2006-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>32 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>AstraZeneca Spain Medical Director, MD</Name></ContactNames></Trial><Trial Id="42636"><Indications><Indication>Head and neck tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>EGFR family tyrosine kinase receptor inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>AstraZeneca plc</Company></CompaniesSponsor><Countries><Country>Brazil</Country><Country>Czech Republic</Country><Country>Lithuania</Country><Country>South Africa</Country><Country>Canada</Country><Country>Malaysia</Country><Country>Latvia</Country><Country>Thailand</Country><Country>Netherlands</Country><Country>Estonia</Country><Country>Russian Federation</Country><Country>Spain</Country><Country>Greece</Country><Country>Australia</Country><Country>US</Country><Country>India</Country><Country>Italy</Country><Country>Israel</Country><Country>Argentina</Country><Country>Norway</Country><Country>Belgium</Country><Country>Slovenia</Country><Country>Sweden</Country><Country>UK</Country><Country>Croatia</Country></Countries><DateChangeLast>2018-06-18T00:00:00Z</DateChangeLast><DateEnd>2007-09-30T00:00:00Z</DateEnd><DateStart>2003-11-30T00:00:00Z</DateStart><Identifiers><Identifier>1839IL/0704</Identifier><Identifier>2004-002662-38</Identifier><Identifier>D7919C00704</Identifier><Identifier>IMEX</Identifier><Identifier>NCT00072878</Identifier><Identifier>NCT00206219</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication><Indication>Nausea</Indication><Indication>Skin rash</Indication><Indication>Stomatitis</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>methotrexate alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>gefitinib alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>477</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of the study was to compare ZD-1839 ( gefitinib 250 and 500 mg) versus methotrexate in head and neck cancer in terms of overall survival. Secondary objectives : To compare ZD-1839 (250 mg and 500 mg) versus methotrexate in terms of symptom improvement, overall objective tumor response (CR + PR) using RECIST criteria, safety and tolerability. To assess quality of life of patients treated with ZD-1839 (250 and 500 mg) versus methotrexate.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Chemotherapy Induced Toxicity</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Markers of Tumor Growth and Progression</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Head and neck tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>IMEX: Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)</TitleDisplay><PatientSegmentTerms><PatientSegment>Head and neck tumor - Subjects with Specific Histological Sub-type of HNC - Subjects with squamous cell carcinoma</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Treatment Resistant Disease - Subjects with chemotherapy resistant disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Epidermal growth factor receptor </BiomarkerName><BiomarkerName> HER2</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2007-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>46 Months</TrialDuration><NumberOfSites>106</NumberOfSites><ContactNames><Name>AstraZeneca Iressa Medical Science Director, MD</Name></ContactNames></Trial><Trial Id="39080"><Indications><Indication>Postmenopausal osteoporosis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Bone resorption inhibitor</Action><Action>Osteoclast inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Sanofi SA</Company></CompaniesCollaborator><CompaniesSponsor><Company>Warner Chilcott plc</Company></CompaniesSponsor><Countries><Country>Poland</Country><Country>Spain</Country><Country>Lebanon</Country><Country>Finland</Country><Country>US</Country><Country>Canada</Country><Country>Brazil</Country><Country>France</Country><Country>Belgium</Country><Country>Estonia</Country><Country>Australia</Country><Country>Hungary</Country><Country>Argentina</Country><Country>Norway</Country></Countries><DateChangeLast>2018-11-29T00:00:00Z</DateChangeLast><DateEnd>2008-04-30T00:00:00Z</DateEnd><DateStart>2005-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2005-002785-10</Identifier><Identifier>2005032</Identifier><Identifier>EFC6062 AND HMRF004M/3001</Identifier><Identifier>MERIT-OP</Identifier><Identifier>NCT00247273</Identifier></Identifiers><IndicationsAdverse><Indication>Arthralgia</Indication><Indication>Constipation</Indication><Indication>Diarrhea</Indication><Indication>Influenza virus infection</Indication><Indication>Pain</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>risedronate sodium alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1294</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this trial was to study the efficacy of a single-dose monthly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily [ 831623 ], [ 867166 ], [ 867460 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Menopause - Assessment of Biomarkers - Assessment of bone markers</EndpointIndex><EndpointIndex>Menopause - Assessment of Bone - Assessment by Bone mineral density (BMD)</EndpointIndex><EndpointIndex>Menopause - Assessment of Bone - Assessment of bone fracture</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Bone - Assessment by Bone mineral density (BMD)</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Bone Resorption Markers - Serum and urinary collagen type I cross-linked C-terminal telopeptide(CTX)</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Bone Resorption Markers - Serum and urinary collagen type I cross-linked N-telopeptide</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Fractures - Assessment of vertebral fractures</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Markers of Bone/Cartilage/Collagen Turnover - Assessment of bone specific alkaline phosphatase</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Markers of Bone/Cartilage/Collagen Turnover - Serum total alkaline phosphatase (ALP)</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Markers of Bone/Cartilage/Collagen Turnover - Urine Type-I Collagen N-telopeptide/Creatinine (NTX / Cr)</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>MERIT-OP: A Study of Monthly Risedronate for Osteoporosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Menopause - Subjects with Premature Menopause - Subjects with surgical menopause</PatientSegment><PatientSegment>Menopause - Subjects with Protocol Specified Menstrual Status - Postmenopausal Subjects</PatientSegment><PatientSegment>Osteoporosis - Subjects at risk of developing disease - Women at risk of developing osteoporosis</PatientSegment><PatientSegment>Osteoporosis - Subjects with Postmenopausal Osteoporosis</PatientSegment><PatientSegment>Osteoporosis - Subjects with Primary Osteoporosis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alkaline phosphatase, tissue-nonspecific isozyme </BiomarkerName><BiomarkerName> Collagen type I trimeric cross-linked peptide</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>49</NumberOfSites><ContactNames><Name>Sal Bartelmo</Name></ContactNames></Trial><Trial Id="38820"><Indications><Indication>Postmenopausal osteoporosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Estrogen receptor modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Bone resorption inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Eli Lilly &amp; Co</Company></CompaniesSponsor><Countries><Country>Mexico</Country><Country>Spain</Country><Country>Netherlands</Country><Country>US</Country></Countries><DateChangeLast>2013-09-14T00:00:00Z</DateChangeLast><DateEnd>2003-09-30T00:00:00Z</DateEnd><DateStart>2003-04-30T00:00:00Z</DateStart><Identifiers><Identifier>8149</Identifier><Identifier>H3S-MC-GGLF</Identifier><Identifier>NCT00532428</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>raloxifene alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>31</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a cross-sectional study to determine, via iliac crest bone biopsies, the effect of long-term treatment with raloxifene on histomorphometry and bone quality in patients who participated in the Continuing Outcomes Relevant to Evista ( CORE ) Study.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Menopause - Assessment of Biomarkers - Assessment of bone markers</EndpointIndex><EndpointIndex>Menopause - Assessment of Bone - Assessment by Bone mineral density (BMD)</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Bone</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Bone - Assessment by Bone mineral density (BMD)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Long Term Effects of Raloxifene Treatment on Bone Quality</TitleDisplay><PatientSegmentTerms><PatientSegment>Menopause - Subjects with Bone Disorders</PatientSegment><PatientSegment>Menopause - Subjects with Protocol Specified Menstrual Status - Postmenopausal Subjects</PatientSegment><PatientSegment>Osteoporosis - Subjects with Postmenopausal Osteoporosis</PatientSegment><PatientSegment>Osteoporosis - Subjects with Primary Osteoporosis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate></PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>7</NumberOfSites></Trial><Trial Id="3511"><Indications><Indication>Non-insulin dependent diabetes</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Insulin sensitizer</Action><Action>PPAR alpha agonist</Action><Action>PPAR gamma agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihyperlipidemic agent</Action><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Bristol-Myers Squibb Co</Company></CompaniesSponsor><Countries><Country>Spain</Country><Country>Argentina</Country><Country>Czech Republic</Country><Country>Poland</Country><Country>Puerto Rico</Country><Country>South Africa</Country><Country>Sweden</Country><Country>Brazil</Country><Country>Canada</Country><Country>France</Country><Country>Netherlands</Country><Country>US</Country><Country>Mexico</Country><Country>UK</Country><Country>Australia</Country><Country>Italy</Country></Countries><DateChangeLast>2013-12-02T00:00:00Z</DateChangeLast><DateEnd>2006-06-01T00:00:00Z</DateEnd><DateStart>2002-05-31T00:00:00Z</DateStart><Identifiers><Identifier>CV168-006</Identifier><Identifier>NCT00240383</Identifier><Identifier>PPAR</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>muraglitazar alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1260</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>A randomized, double-blind, dose-ranging, dose comparison-controlled trial to determine the safety and efficacy of muraglitazar in subjects with type 2 diabetes.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Dose Comparison</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Change in HbA1c</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of lipid profiles - Assessment of Total Cholesterol</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of lipid profiles - HDL-C (High-density lipoprotein cholesterol)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of lipid profiles - LDL-C (Low-density lipoprotein cholesterol)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of lipid profiles - Non-HDL levels</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of lipid profiles - Triglyceride levels (TG)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>PPAR: Dose Ranging Study With LT, Monotherapy, PPAR</TitleDisplay><PatientSegmentTerms><PatientSegment>Non-insulin dependent diabetes - Subjects with Good Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2006-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>268</NumberOfSites></Trial></SearchResults></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput>